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1. Introduction 
1.1 Atherosclerosis 
Cardiovascular disease (CVD) is a group of disorders of the heart and blood 
vessels, including stroke, heart failure and coronary heart disease, which 
affect the cardiovascular system. The major cause of morbidity and death 
worldwide is coronary heart disease, also called coronary artery disease 
(CAD). The underlying pathology of CAD is atherosclerosis1.  
Atherosclerosis is characterized by a chronic inflammatory process in the 
vessel wall with an initial endothelial dysfunction, triggering the formation of 
fatty streaks that can evolve in more progressed atherosclerotic plaques2, 3. 
This inflammatory response is driven by many cells, growth factors, cytokines 
and chemokines3.  
The development of atherosclerosis is initiated by an endothelial 
dysfunction of the arterial wall2-4, which leads to an increased infiltration of lipid 
components, like low-density lipoprotein (LDL), into the vessel wall and 
induces the adhesion of leukocytes and activated platelets to the damaged 
endothelial area5 (Figure 1A). Triggered by a local gradient of chemoattractant 
cytokines, monocytes are then recruited to the damaged sites of the arterial 
wall and migrate into the subendothelial space, where they differentiate into 
macrophages. By taking up oxidized LDL (oxLDL), macrophages transform 
into foam cells, which accumulate to form early lesions (fatty streaks) in the 
intima3 (Figure 1B). With time, plaques become bigger due to an increasing 
accumulation of inflammatory cells (mainly macrophages and T cells)6 and 
extracellular lipids. A necrotic core is formed by dying macrophages that have 
taken up too many lipids and apoptotic cell fragments. At the same time, 
smooth muscle cells (SMCs) begin to proliferate and migrate to the plaque 
area. They produce extracellular matrix components as collagen, triggering the 
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formation of a fibrous cap, which covers the plaque beneath the endothelium 
(Figure 1C). The progression of an atherosclerotic plaque by further deposition 
of extracellular matrix components can induce an arterial luminal narrowing 
(stenosis)4. Additionally, neovascularization and hemorrhage can occur in 
progressed atherosclerotic lesions. The continuing influx and activation of 
macrophages cause a thinning or degradation of the fibrous cap by the release 
of metalloproteinases and other proteolytic enzymes, characteristic for an 
unstable plaque or rupture-prone lesion2, 4. Such unstable lesion can 
eventually result in plaque erosion or rupture and trigger the formation of a 
thrombus (Figure 1D), which can block the blood vessel and induce stroke, 
myocardial infarction or coronary syndrome4, 5.  
 
 
A B 
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Figure 1: Evolution of atherosclerosis. A, Endothelial dysfunction of the arterial wall 
is the initial step of atherosclerosis, inducing the adhesion of leukocytes and activated 
platelets to the damaged endothelial area and increased endothelial permeability to 
lipoproteins. B, Monocytes are recruited to the damaged site of the arterial wall and 
differentiate into macrophages. Macrophages transform into foam cells by taking up 
oxLDL, leading to the formation of early lesions (fatty streaks). C, By accumulation of 
inflammatory cells, e.g. foam cells and T cells, and extracellular lipids, a necrotic core 
is formed. Proliferation and migration of SMCs to the plaque area, together with the 
deposition of a collagen-rich matrix, contribute to the formation of a fibrous cap. D, 
Neovascularization and hemorrhage can occur in a progressed atherosclerotic lesion. 
A thinning or degradation of the fibrous cap characterizes an unstable or 
rupture-prone lesion, which can eventually result in plaque erosion or rupture and 
formation of a thrombus. (Figure from Ross R. et al.2) 
 
 
1.2 Restenosis and Mechanical Denudation 
Since atherosclerosis is the main cause inducing cardiovascular disease, 
including myocardial infarction and stroke, management of patients with 
severe atherosclerotic plaques has evolved over the years. Treatment options 
differ depending on the grade of severity and include lifestyle changes, 
medicines, and medical procedures or surgery. Surgical treatments as 
angioplasty and stenting techniques, are widely used for treating patients with 
atherosclerotic disease7, 8. Balloon angioplasty and stent implantation aim to 
remove the vascular obstruction in order to expand the inner diameter of the 
artery. With this method the blood flow to the heart is improved. However, 
limitations occur after the treatment, one of which is “restenosis”7, 8. 
Restenosis is the re-narrowing of a dilated artery initiated by mechanical 
denudation of the endothelium during intervention. It is a major limitation of 
surgical intervention techniques, and often occurs in the first 3-6 months after 
treatment7-9. Figure 2 shows restenosis of a stent-widened coronary artery. 
With an expanded stent, a plaque in the coronary artery is compressed to 
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widen the artery and allow normal blood flow. However, stent insertion is 
associated with endothelial injury, triggering apoptosis of medial SMCs 
followed by a hyperproliferative response and the formation of an SMC-rich 
neointima. Over time, the neointimal lesion grows through the stent, causing 
re-narrowing of the artery, which is called restenosis. 
 
 
 
Figure 2: Restenosis of a stent-widened coronary artery. A, An atherosclerotic 
plaque is compressed by an expanded stent to widen the artery lumen, allowing 
normal blood flow. B, Triggered by endothelial injury during stent insertion, a 
neointimal lesion develops and grows through the stent over time, causing 
re-narrowing of the artery lumen (Figure from 
http://www.nhlbi.nih.gov/health/health-topics/topics/angioplasty/risks.html). 
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Although restenosis entails a chronic inflammation of the vessel wall in 
response to injury8, the underlying pathological process triggering restenosis is 
different compared with native atherosclerosis9. A native atherosclerotic 
plaque is formed by a chronic process of lipid accumulation through 
endothelial dysfunction, inducing inflammatory cell recruitment. Vascular 
SMCs contribute to plaque stabilization through the formation of a protective 
fibrous cap. In contrast, restenosis is triggered by intervention-induced 
endothelial injury or denudation during mechanical dilatation of the blood 
vessel, triggering the formation of an SMC-rich neointimal lesion9, 10. After 
endothelial disruption and an initial apoptotic response of vascular SMCs, 
SMCs from the media start to proliferate and migrate to the subendothelial 
space10, 11. Thus, SMCs drive injury-induced neointima formation, whereas 
they are considered protective in native atherosclerosis by forming a protective 
fibrous cap over a native atherosclerotic lesion.  
However, similarly to native atherosclerosis, mechanical denudation also 
induces vascular inflammation. The presence of an injured and incomplete EC 
layer allows leukocytes from the blood stream to easily accumulate at the site 
of injury. Chemokines and inflammatory cytokines are produced by the 
accumulating inflammatory cells as well as by vascular SMCs and endothelial 
cells (ECs). These mediators trigger a further recruitment of inflammatory cells 
(e.g. monocytes), which contribute to vascular inflammation and neointima 
formation. 
Also, chemokines and cytokines mobilize bone marrow-derived progenitor 
cells, as endothelial and smooth muscle progenitor cells, to the site of injury12. 
The role of progenitor cells in injury-induced neointimal hyperplasia is 
discussed in more detail in chapter 1.4. 
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1.3 Reendothelialization 
The endothelium is the innermost layer of a vessel and consists of a 
monolayer of ECs. Healthy vascular endothelium modulates vascular tone and 
SMC proliferation13 and protects against subendothelial lipid accumulation, 
inflammatory cell infiltration and thrombus formation14. In pathological 
conditions or after vessel intervention, the normal regulatory functions of ECs 
are altered or disrupted, which is described as “endothelial dysfunction” and 
commonly initiates atherosclerosis or restenosis13.  
Mechanically-induced damage of the endothelial layer of the vessel wall is 
followed by proliferation and migration of viable, neighboring ECs to the injured 
site, with the aim to restore the damaged endothelium. This process is called 
reendothelialization and is triggered by a lot of biological factors such as 
growth factors, cytokines and chemokines. 
Reendothelialization plays a crucial protective role against neointima 
formation. It has been reported that EC seeding on an injured vessel wall of 
atherosclerotic rabbits significantly reduces the neointimal area and enhances 
endothelial recovery, followed by a reduction of restenosis15. Also EC implants 
after vascular injury in pigs revealed a delayed neointima formation16. 
Moreover, restoration of the endothelium is inversely related to neointimal 
thickness. An accelerated regeneration of the endothelium protects against 
neointima formation, whereas an increased neointimal hyperplasia is often 
associated with a delayed reendothelialization17, 18.  
In addition to neighboring ECs contributing to endothelial repair, 
reendothelialization is also influenced by circulating endothelial progenitor 
cells (EPCs, more details in Chapter 1.4). EPCs are derived from bone marrow 
after vessel injury19-21 and contribute to endothelial repair through 
differentiation/maturation into mature ECs22 or by stimulating migration/  
proliferation of local, mature ECs through cytokine production (Figure 3). 
Studies have shown that transplantation of EPCs enhances 
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reendothelialization in prosthetic vascular grafts in human23, 24 and in injured 
vessels of rabbits associated with an inhibitory effect on neointimal 
hyperplasia24. Also, statin therapy enhances the number of circulating EPCs22, 
and simultaneously promotes reendothelialization25. Although EPCs may 
contribute to endothelial repair by differentiating locally into ECs, the current 
view rather supports a paracrine role for EPCs, in which EPCs produce various 
proangiogenic cytokines and growth factors that promote proliferation and 
migration of preexisting local ECs26. 
 
 
 
Figure 3: Reendothelialization. Reendothelialization is a process of EC recovery 
driven by migration and proliferation of local mature ECs. Furthermore, bone 
marrow-derived circulating EPCs play an important role in reendothelialization, either 
by differentiation into mature ECs or through paracrine stimulation of local ECs.  
Mobilization of EPCs to an injured vascular site and their differentiation is driven by 
multiple signaling molecules, e.g. chemokines and growth factors (Figure from Kabir 
AM et al.27). 
 
 
Mobilization and recruitment of EPCs to injured sites are mediated by 
chemokines and their receptors (which are discussed in more detail in Chapter 
1.5) Together with its ligand CXCL12, the chemokine receptor CXCR4 is 
important for the mobilization of progenitor cells from the bone marrow28-30 . 
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Furthermore, CXCR4 has been shown to be involved in mediating the 
recruitment of EPCs to injury-induced neointima21, 31, contributing to 
reendothelialization of denudated vessels20, 21. Also, the chemokine receptor 
CXCR2 on EPCs contributes to endothelial recovery32, as inhibition of CXCR2 
on EPCs reduced the incorporation of injected EPCs in an injured carotid 
artery with 30 percent31. Finally, also chemokine receptor CXCR7, a second 
chemokine receptor for CXCL12, is expressed on the EPC surface, and a 
declined expression of CXCR7 on EPCs from patients with hypertension was 
recently related to a reduced in vivo reendothelialization capacity of EPCs33.  
In summary, reendothelialization is a complex process of EC recovery, 
driven by the proliferation and migration of mature ECs and the recruitment of 
circulating EPCs. Multiple signaling molecules are involved in this process, e.g. 
chemokines. Reendothelialization plays an important role in protection against 
neointimal proliferation after vascular denudation, and in reducing the risk of 
thrombosis.  
 
 
1.4 Endothelial Progenitor Cells (EPCs) 
EPCs originate from the bone marrow, can be mobilized by chemokines and 
cytokines and recruited to sites of injury, where they can differentiate into 
mature ECs or drive proliferation and migration of resident mature ECs through 
paracrine effects. Human EPCs were first described by Asahara et al. in 1997. 
They showed that human CD34+ mononuclear blood cells could adopt an 
endothelial phenotype after specific culturing conditions in vitro, and these 
cultured “EPCs” contributed to active angiogenesis in animal ischemic 
models34. Since this discovery, EPCs have been widely investigated. Mainly, 2 
categories of EPCs have been studied. “Culture-derived EPCs” are EPCs that 
are derived after culturing of specific isolated blood cells under specific defined 
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conditions. On the other hand, “circulating EPCs” refers to circulating 
progenitor cells in the blood, which can differentiate into mature ECs in specific 
conditions35-37. However, connection between these culture-derived and 
circulating EPCs is still unclear. 
Two kinds of culture-derived EPCs have been reported, being early and 
late EPCs, the latter also called late outgrowth EPCs/ECs35, 38. Early EPCs can 
influence EC regeneration through still unclear cellular and paracrine effects, 
but do not have the ability themselves to directly mediate vasculogenesis and 
EC regeneration. In contrast, late outgrowth ECs mostly express endothelial 
lineage markers without significant amounts of hematopoietic surface markers 
and possess the ability to form intact vascular networks35.  
The surface markers of circulating EPCs are not well defined, and various 
surface markers are being used by different researchers to quantify this cell 
population, severely complicating EPC research. Human circulating EPCs 
have mostly been characterized by using vascular endothelial growth factor 
receptor 2 (VEGFR-2 or FLK1) and CD34 as markers. Whereas CD34 is 
shared by human circulating EPCs and hematopoietic stem cells (HSCs), 
VEGFR-2 was shown to be only present on circulating EPCs and not HSCs36. 
CD34 is also expressed on mature ECs, but to a lower extent. Furthermore, 
CD133 is often included as an additional human progenitor cell marker, both 
present hematopoietic as endothelial progenitor cells, but its expression is lost 
when EPCs differentiate into mature ECs39. Also in mouse, the definition of 
“circulating EPCs” is really vague and undefined. Several mouse studies used 
Sca1+Flk1+ as cell markers in flow cytometric analysis for quantifying 
circulating EPCs40, 41. 
It has been reported that dysfunction and reduced levels of EPCs in clinical 
disease states was associated with poor wound healing, e.g. in diabetes42. 
Interestingly, subjects with increased numbers of circulating EPCs show a 
better endothelial function as measured by increased brachial reactivity, 
independent of their Framingham risk score quantifying cardiovascular risk26. 
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Furthermore, a reduction of circulating EPC number revealed endothelial 
dysfunction and also high risk factors of atherosclerotic disease43, 44. 
Mechanistically, bone marrow-derived EPCs have the ability to be 
mobilized into the peripheral blood and migrate to damaged sites to induce 
endothelial recovery. As such, EPCs have been indicated to play a crucial role 
in reendothelialization after vessel injury19, 45 as well as neovascularization in 
ischemic tissue19, 46. For example, transplantation of EPCs in rats showed a 
significant enhancement of new blood vessel formation after myocardial 
infarction47 and hind limb ischemia48, 49. In context of vessel injury, 
reendothelialization of denudated vessels could be accelerated by the same 
strategy, i.e. EPC transplantation, which was associated with a reduction in 
neointimal hyperplasia24, as already discussed in more detail in Chapter 1.3. 
Furthermore, studies have shown that through statin treatment or physical 
exercise the number of circulating EPCs is increased, leading to a significant 
enhancement of endothelial recovery and a declined neointima formation after 
vascular injury40, 50, 51. In conclusion, EPCs contribute to endothelial recovery 
and vascular repair and in that way may reduce the risk of cardiovascular 
disease19, 44. 
EPCs can be mobilized by cytokines and chemokines from the bone 
marrow into the peripheral blood and damaged tissue in response to injury21, 52, 
53
. Vascular endothelial growth factor (VEGF) can regulate EPC mobilization 
and recruitment through its receptor VEGFR-2 expressed on the EPC 
surface52, 54, 55. Similarly, it has been reported that hematopoietic progenitor 
cell (HPC) mobilization was induced by granulocyte colony-stimulating factor 
(G-CSF)56. Furthermore, granulocyte monocyte colony-stimulating factor 
(GM-CSF) has the ability to direct circulating EPCs to ischemic hind limb tissue, 
triggering enhanced neovascularization57. Also, chemokines like CXCL12 and 
its receptor CXCR4 contribute to EPC mobilization15, 28, 29, as is discussed in 
more detail in Chapter 5.2. In addition, macrophage migration inhibitory factor 
(MIF), a ligand for the chemokine receptors CXCR4 and CXCR258, has been 
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reported to trigger EPC recruitment and migration to ischemic myocardial 
cells59.  
 
 
Figure 4: EPCs. EPCs are derived from bone marrow and can be mobilized to sites of 
injury, where they can proliferate and differentiate into mature ECs. In this way, EPCs 
are involved in neovascularization and reendothelialization. 
 
 
In conclusion, EPCs are a heterogeneous cell group, which in phenotype 
and function still need to be defined in more detail. Several cytokines and 
chemokines are able to promote EPC mobilization from the bone marrow and 
recruitment to injured sites, where they contribute to reendothelialization after 
vessel denudation20, 21 and neovascularization of ischemic tissue53 (Figure 4). 
This gives a new view on the therapeutic potential to increase the EPC number 
by cytokine or chemokine treatment, to accelerate vascularization or recovery 
of damaged vessels in order to abate the risk on cardiovascular disease. 
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1.5 Chemokines and Chemokine Receptors 
1.5.1 Definition, Classification and Function 
In 1992 the term “chemokine” was introduced as an abbreviation of 
“chemotactic cytokine”. The first chemokine that was characterized, is CXCL8, 
which is also known as interleukin-8 (IL-8)60, 61. Chemokines or 
chemoattractant cytokines are a family of structurally related low molecular 
weight glycoproteins with a molecular weight of the single polypeptides of 
around 8-10 kDa and a length range from 70-100 amino acids3, 62. 
Chemokines can guide the movement of leukocytes in homeostatic condition 
and also direct the migration of immune cells to inflamed or injured sites in 
pathological condition63-65. There are approximately 50 known chemokines, 
which are classified in 4 subgroups based on their structure, and more 
specifically on the location of the first two cysteine residues. These four 
subfamilies are termed C, CC, CXC and CX3C3, 62, 64-66 (Figure 5). 
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Figure 5: Classified chemokine structures. Four different subgroups of chemokines 
exist: C, CC, CXC and CX3C. All chemokines exhibit the same basic structural fold 
known as the “chemokine fold”, consisting of a short, disordered N-terminal region 
containing the characteristic cysteine motif, an extended N-loop region, 3 antiparallel 
β-strands linked by turns designated 30s-, 40s- and 50s-loop, and finally a C-terminal 
α-helix. (Figure from http://en.wikipedia.org/wiki/File:ChtxChemokineStruct.png). 
 
 
The group of “C chemokines” has only one member, Lymphotactin (XCL1), 
which contains a single cysteine residue with a chemotactic function towards 
lymphocytes67. Similarly as for the C group, only one member has been 
discovered until now in the CX3C group, in which the first N-terminal pair of 
cysteine residues is separated by 3 other amino acids62. This CX3C chemokine 
is named fractalkine (CX3CL1), a large chemokine of 373 amino acids that 
contains in addition to the typical chemokine domain an extended mucin-like 
domain, which allows its binding to the surface of cells, and a cytoplasmic 
domain3. This cell-bound CX3CL1, which is for example found on activated 
ECs, can enhance the adhesion of leukocytes, whereas a soluble version of 
the chemokine has the ability to induce chemotaxis of monocytes and T cells67. 
The CC chemokine family contains two adjacent cysteine residues and 
consists of around 28 members (CCL1 – CCL28), binding to 10 known 
chemokine receptors (CCR1 – CCR10)65, 68. The group of CC chemokines 
plays an important role in mediating chemotaxis of leukocytes, as T cells, 
monocytes, macrophages and neutrophils, in chronic inflammatory 
conditions65. CC chemokines like CCL1 (I-309), CCL2 (monocytes 
chemoattractant protein-1, MCP-1), CCL3 (macrophage inflammatory protein, 
MIP-1α), CCL4 (MIP-1β) and CCL5 (regulated on activation normal T cell 
expressed and secreted, RANTES) have been found to be expressed in 
atherosclerotic lesions65, 69-71. CCR2, the main receptor for CCL2, is expressed 
on T-lymphocytes, monocytes and macrophages, and has been shown to 
mediate monocyte migration into the vascular wall72. Deletion of CCL2 or its 
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receptor CCR2 in mice revealed reduced atherosclerotic lesion size 
associated with less macrophage deposits73, 74. Similarly, T-cell 
chemoattractant pulmonary and activation-regulated chemokine 
(PARC/CCL18) was found to be highly expressed by macrophages in human 
atherosclerotic lesions75. Epstein-Barr virus-induced molecule 1 ligand 
chemokine (ELC/CCL19), which is also able to recruit T-cells76, was expressed 
not only by macrophages but also by medial SMCs in plaque regions75. A 
neutralizing antibody treatment against CCL12 revealed a decreased lesion 
size, concomitant with a reduced content of leukocytes and macrophages and 
an increased content of SMCs and collagen, indicating a relatively stable 
plaque phenotype in the absence of functional CCL1277.  
CXC chemokines contain one amino acid residue in between the first and 
second cysteine residue3, 62, 65. Based on the presence or absence of a 
glutamatic acid-leucine-arginine (ELR) motif preceding the first conserved 
cysteine residue, the CXC chemokine group can be divided into two subgroups, 
namely ELR+ and ELR- 78, 79. ELR+ CXC chemokines have the ability to attract 
neutrophils to inflammatory sites, as for example shown for CXCL8 in vitro and 
in vivo80 through binding to its receptor CXCR281. In addition, it has been 
reported that CXCL8 acts on ECs and leukocytes through its receptors CXCR1 
and CXCR2 to enhance angiogenesis and immune infiltration, respectively, 
and similarly also enables cancer cells to survive and migrate in an 
inflammatory microenvironment82-84. Moreover, ELR+ CXC chemokines have 
the ability to mediate the mobilization of EPCs from the bone marrow and their 
recruitment to angiogenetic sites85. In contrast to ELR+ CXC chemokines, ELR- 
CXC chemokines rather tend to be attractants for natural killer (NK) cells and B 
and T lymphocytes61, 86, 87, and are mostly not angiogenic, some even 
angiostatic88. For example, ELR- CXC chemokine platelet factor-4 
(PF-4/CXCL4) mediates chemoattraction of dendritic cells (DCs), NK cells and 
T lymphocytes and inhibits angiogenesis through its receptor CXCR389, 90. 
Similarly, ELR- CXC chemokine interferon-γ inducible protein-10 
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(IP-10/CXCL10) functions as an angiostatic factor and can attract anti-tumoral 
lymphocytes via its receptor CXCR391. However, stromal cell-derived factor-1α 
(SDF-1α/CXCL12) is an exception in this ELR- CXC chemokine group; 
together with its receptor CXCR4 it plays an important role in stimulating 
angiogenesis61, 91, 92. Taken together, the CXC chemokine family is generally 
involved in modulation of angiogenesis, either as angiogenic factors as for 
ELR+ CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 
and CXCL8)85 or as angiostatic regulators as for certain ELR- CXC 
chemokines(CXCL4, CXCL9, CXCL10, CXCL11 and CXCL14)61, 65, 85. 
Chemokine receptors are seven transmembrane G protein-coupled 
receptors (GPCRs) and are classified according to the chemokines they bind. 
Around 20 chemokine receptors have been identified93. Since there are more 
chemokines than receptors, some receptors can bind more than one 
chemokine. Also the other way around, some chemokines are able to bind to 
several chemokine receptors94, 95 (Figure 6). Cells are influenced by 
chemokines through activation of the corresponding chemokine receptors65.  
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Figure 6: Chemokine ligands and their receptors. Since there are more 
chemokines than receptors, some receptors can bind to more than one chemokine. 
(Figure from White GE et al.68) 
 
 
Chemokines and their receptors are expressed by a lot of cells, such as 
ECs, SMCs, leukocytes, epithelial cells, tumor cells and fibroblasts78. They 
have an important function in both homeostatic and inflammatory conditions. 
For example, chemokines and their receptors are involved in directing 
(progenitor) cell migration during embryonic development, wound healing, 
adaptive and innate immunity as well as angiogenesis. Chemokines and their 
receptors also drive cell mobilization and recruitment of inflammatory cells to 
specific sites of chronic inflammation, potentially leading to tumorigenesis and 
autoimmune diseases85. In addition to inducing cell chemotaxis, chemokines 
play an important role in cell activation96. For example, chemokines can 
modulate gene expression and trigger the release of inflammatory mediators 
from e.g. macrophages and neutrophils. Furthermore, chemokines play an 
important role in cell arrest96, for example of leukocytes on activated ECs, an 
important step in atherosclerosis. In this leukocyte adhesion cascade, there 
are mainly three steps, which are selectin-mediated rolling, 
chemokine-triggered integrin activation and integrin-mediated arrest. In 
response to inflammation, EC-secreted chemokines induce activation of 
leukocytic integrins through chemokine receptor signaling in the leukocytes, 
allowing strong binding and arrest of rolling leukocytes through their activated 
integrins97. As leukocyte adhesion is strongly mediated by selectins, 
chemokines and cell adhesion molecules98, 99, these molecules are important 
in the development of atherosclerosis. 
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1.5.2 The Chemokine Receptor CXCR4 
The chemokine receptor CXCR4 is also known as fusin or CD184. It is 
expressed on many cell types, including monocytes, platelets, macrophages, 
SMCs, ECs and notably hematopoietic stem cells100, and is involved in 
processes of hematopoiesis, vasculogenesis, neurogenesis and 
cardiogenesis101, 102. Studies of Cxcr4-deficient mice are not possible, as 
genetic deletion of either Cxcr4 or its ligand Cxcl12 in mice induces perinatal 
death due to defects in bone marrow colonization, B cell lymphopoiesis and 
cardiac septa development29, 101. Furthermore, CXCR4 is involved in 
mobilization of bone marrow-derived progenitor cells, including EPCs103. In this 
context, activation of CXCR4 by sphingosine-1-phosphate (S1P), which is a 
bioactive lipid and involved in EC migration and proliferation, can mediate EPC 
mobilization and promote neovascularization, suggesting that S1P agonists 
may have therapeutic potential in progenitor cell therapy to improve EPC 
function in patients with CAD104. Furthermore, chronic daily treatment with 
AMD3100, which is an antagonist of CXCR4, partially inhibited vascular 
recovery effectively blocking VEGF-mediated revascularization of ischemic 
hindlimb in mice105. Thus, these data suggest that activation of CXCR4 plays a 
pivotal role in revascularization of ischemic tissues by promoting EPC, 
mobilization chemotaxis and/or function. In context of progenitor cell 
mobilization during restenosis, CXCR4 seems to play a double-edged role. On 
the one hand CXCR4 is protective by mediating the recruitment of EPCs. On 
the other hand, CXCR4 drives neointimal hyperplasia by recruiting smooth 
muscle progenitor cells (SPCs), as will be explained in more detail in the next 
chapter. 
CXCR4 expression has been found in atherosclerotic plaques. However, 
the role of CXCR4 in native atherosclerosis remains to be further investigated. 
Chronic blockade of CXCR4 by systemic treatment with a CXCR4 inhibitor led 
to leukocytosis and an increased recruitment of neutrophils to atherosclerotic 
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plaques, inducing a pro-inflammatory plaque phenotype106, but cell 
type-specific effects of CXCR4 remain unclear. 
In conclusion, CXCR4 seems to play a double-edged role in injury-induced 
restenosis, whereas its role in native atherosclerosis remains unclear. Further 
research is required before a potential application of CXCR4 antagonists in 
context of CAD could be considered. 
The chemokine CXCL12, also known as SDF-1α, is the best-known ligand 
of CXCR4. Like its receptor CXCR4, CXCL12 is ubiquitously expressed and 
essential for bone marrow engraftment, homeostasis, vascularization during 
embryogenesis, as well as (hematopoietic) progenitor cell mobilization107-110. 
Cxcl12 could trigger the mobilization of EPCs enhancing ischemic 
neovascularization111. Furthermore, CXCL12 expression can be detected in 
atherosclerotic lesions112, and a decreased CXCL12 plasma levels in patients 
with unstable angina suggested that CXCL12 may have an anti-inflammatory 
function and may play a beneficial role in CAD113. Also, it has been shown in 
an Apoe-/- mouse model that Cxcl12 could promote the stabilization of 
atherosclerotic plaques by mediating the mobilization of SPCs114. On the other 
hand, a study has shown that the CAD risk alleles of two single-nucleotide 
polymorphisms (SNPs), rs1746048 and rs501120, are related to higher 
CXCL12 plasma levels, suggesting a disadvantageous effect of CXCL12 in 
CAD115. 
Furthermore, CXCL12 seems to play a double-edged role in injury-induced 
restenosis by mediating the mobilization of EPCs vs. SPCs, as will be 
discussed in more detail in chapter 1.5.3. The role of CXCL12 in vascular and 
inflammatory cells in context of CAD remains to be further investigated, 
similarly as for its receptor CXCR4. 
Recently, it has been discovered that MIF is another non-canonical 
chemokine ligand of CXCR4. MIF was initially known as an important cytokine 
in acute and chronic inflammatory diseases64, 116. Recent evidence revealed 
that MIF also harbors a chemokine-like function and can bind to the chemokine 
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receptors CXCR2 and CXCR4117. This was associated with a pro-atherogenic 
effect of MIF, as blockade of MIF impaired CXCR4-mediated T cell recruitment, 
and CXCR2-mediated monocyte recruitment, resulting in atherosclerotic 
plaque stabilization and even regression117. Comparably, blockade of Mif 
reduced injury-induced neointima formation118 and reduced neointimal 
macrophage content119 in an animal model of experimental angioplasty and 
wire-mediated vascular injury, respectively, again suggesting a 
pro-inflammatory role of MIF. However, MIF has also been described to 
mediate EPC chemotaxis59, which may be mediated by binding to CXCR2 and 
CXCR4 on the EPC surface31. So similarly to CXCL12 and CXCR4, MIF also 
seems to be associated with protective roles through EPC mobilization and 
recruitment, which could play a beneficial role in context of injury-induced 
restenosis and myocardial ischemia.  
 
 
1.5.3 Role of CXCR4 in Injury-induced Restenosis 
As explained in chapter 1.2, restenosis is caused by intervention-induced 
endothelial injury, and mediated by arterial remodeling and the formation of 
neointimal lesions mainly containing inflammatory leukocytes and SMCs10, 120. 
An accelerated endothelial recovery of the injured vessel is important to 
reduce the risk on restenosis18 and EPCs contribute to this reendothelialization 
step after vessel injury19, 45. In this process, chemokines and their receptors 
play an essential role. CXCR4 is a key chemokine receptor in regulating 
homing of bone marrow-derived progenitor cells to an injured vascular wall121. 
Blockade of CXCR4 signaling resulted in decreased recruitment of EPCs to 
injured arteries31. Moreover, Cxcr4 gene transfer increased the 
reendothelialization capacity of EPCs in mice with denuded carotid arteries122. 
Similarly, Cxcl12 was shown to be involved in the mobilization and recruitment 
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of EPCs after arterial injury41. Thus, these studies reveal a beneficial role of 
the Cxcl12/Cxcr4 axis in injury-induced restenosis by directing the migration of 
protective EPCs. 
On the other hand, accumulating studies have demonstrated that Cxcr4 
mediates the recruitment of SPCs to injury-induced neointima21, 49. In Apoe-/- 
mice, vessel injury induced upregulation of the Cxcr4 ligand Cxcl12 in the 
injured vessel. Furthermore, the plasma level of Cxcl12 was significantly 
increased after carotid artery injury, followed by an enhanced mobilization of 
circulating Lin-Sca1+ progenitor cells, often referred to as SMC progenitor 
cells123. A decreased neointimal hyperplasia and neointimal SMC content after 
arterial injury were observed in Apoe-/- mice transplanted with Cxcr4-/- bone 
marrow or after blockade of Cxcl12, and was associated with a reduced 
mobilization of circulating SMC progenitors21. Also, interference with the 
Cxcl12/Cxcr4 axis by blocking Cxcr4 with a Cxcr4 antagonist induced less 
mobilization of SMC progenitor cells and reduced neointima formation after 
arterial injury124.  
Together, these studies reveal a double-edged role for Cxcr4 and Cxcl12 in 
injury-induced restenosis by mediating the recruitment of either protective 
EPCs vs neointima-driving SPCs. 
However, specific effects on vascular vs inflammatory cells in context of 
mechanical injury still remain unknown. Therefore, it is necessary to 
investigate the CXCL12/CXCR4 axis in more detail, to allow the development 
of new therapeutic treatment strategies to treat patients with cardiovascular 
disease. 
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2 Aims of this Study 
It has been reported that the Cxcl12/Cxcr4 axis mediates SPC recruitment to 
injured vessels, driving injury-induced neointimal hyperplasia21. However, the 
EC-specific functions of Cxcr4 in arterial remodeling remain totally unclear. 
Nonetheless, reendothelialization is a major step after mechanical injury, with 
an important role in protecting against neointima formation. This study aimed 
to investigate the role of endothelial Cxcr4 in neointima formation after 
vascular injury, using a model of wire-mediated carotid artery injury in mice 
with a tamoxifen-inducible, EC-specific Cxcr4-deficiency. 
The first goal of this study was to evaluate the role of endothelial Cxcr4 in 
reendothelialization after carotid artery injury. Secondly, the study aimed to 
investigate the effect of endothelial Cxcr4 on EPC recruitment and endothelial 
proliferation and migration. Finally, the mechanism underlying the effects of 
endothelium-specific Cxcr4-deficiency on neointima formation were further 
studied.
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3 Material and Methods 
3.1 Material 
3.1.1 General Equipment 
Table 1: List of general equipment 
General Equipment Manufacturer 
Autoclave Systec 2540EL (Systec, Germany) 
Balance Sartorius, Germany 
Centrifuges  Eppendorf 5417C (Eppendorf, Germany) 
Eppendorf 5425 (Eppendorf, Germany) 
Flow cytometer FACSCanto-II (BD Biosciences, USA) 
Fluorescence plate reader  Infinite M200 (Tecan, Germany) 
Incubator Hera Cell 240 (Fisher Scientific GmbH, 
Germany) 
Laminar flow hood  Herasafe (Heraeus, Germany) 
Microscopes Leica DM2500 (Leica, Germany) 
CCD camera (JVC, USA) 
EVOS FL (Life Technologies, Germany) 
Microtome Leica RM2245 (Leica, Germany) 
pH-meter InoLab level 1 (WTW, Germany) 
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3.1.2 Consumables 
Table 2: List of consumables 
Consumable Manufacturer 
6-well plates (flat bottom) Becton Dickinson, USA 
96-well plates (flat bottom) Becton Dickinson, USA 
96-well plates (round bottom) Nunc, Denmark 
Culture flasks (T25, T75) Greiner Bio-one, Germany 
EDTA-coated tubes Sarstedt, Germany 
FACS-tubes BD Biosciences, USA 
Glass microscope slides Thermo Scientific, Germany 
Heparin-coated tubes Sarstedt, Germany 
Serological pipettes (5 ml, 10 ml, 25 ml) Corning, USA 
Syringes (1 ml) Braun, Germany 
Syringes (2 ml, 5 ml, 10 ml, 20 ml) Terumo, Belgium 
 
 3.1.3 Buffers, Solutions and Media 
Table 3: List of buffers, solutions and media 
Buffer/Solution/Medium Composition/Manufacturer 
0.5% HCl-Ethanol 995 ml 70% ethanol, 5 ml 37% HCL 
Antibody diluting solution Phosphate buffered saline (PBS) containing 
10% blocking solution 
Anesthesia  0.05 ml Xylazine (final dose: 10 mg/kg), 0.1 ml 
Ketamine (final dose: 100 mg/kg) and 0.85 ml 
0.9% sodium chloride 
Blocking solution PBS containing 1% bovine serum albumin 
(BSA ) and 2.5% horse serum 
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Collagenase solution Steril PBS containing 1% of Collagen G 
(Biochrom, Germany)  
Diluting solution 0.9% NaCl 
Endothelial cell growth 
medium 
Endothelial cell growth medium MV (Promocell, 
Germany), 0.1% gentamicin (Gibco, Germany) 
FACS staining buffer 2% mouse serum, 2% human serum, 2% rabbit 
serum, 2% BSA in PBS 
Hank’s complete solution 1 x HBSS (Invitrogen, USA) containing 0.3 mM 
EDTA, 0.1% BSA in Millipore water  
Paraformaldehyde (PFA) 
fixation solution 
4% PFA, 5% sucrose and 0.02 M EDTA in PBS 
(pH 7.4) 
PBS with/without 2 mM MgCl2, steril (PAA, Austria) 
Red blood cell lysis buffer 0.8% NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA 
in Millipore water (pH 7.4) 
Sirius Red solution 0.1% sirius red in picric acid 
Sodium citrate cooking 
buffer 
12.6 ml of 0.1 M citric acid, 57.4 ml of 0.1 M 
natrium-citrate dehydrate and 0.35 ml Tween 
20 were dissolved in 630 ml distilled water 
Tamoxifen solution Tamoxifen (Sigma-Aldrich, USA) in Miglyol 
(Caelo, Germany)  at a concentration of 
20mg/ml 
Vitro-Clud mounting 
medium 
Vitro-Clud (Augenbrinck, Germany) in xylene 
Weigert’s A solution 10 g hematoxylin, 1000 ml 96% ethanol 
Weigert’s B solution 40 ml 29% ferric-chloride-solution, 950ml 
distilled water, 7.5ml 37% HCl 
X-gal reaction buffer PBS containing 5 mM potassium ferricyanide, 5 
mM potassium ferrocyanide, 2 mM MgCl2, 
0.02% Nonidet P-40, 0.01% Na-deoxycholate 
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and 1 mg/ml X-gal  
X-gal stock solution 40 mg/ml X-gal in dimethylformamide (stored at 
-20°C in dark) 
 
 
3.1.4 Reagents and Chemicals 
Table 4: List of reagents and chemicals 
Reagent/Chemical Manufacturer 
Hydrochloric acid (HCl) Merck, Germany 
Human serum Innovative Research, USA 
Isoflurane Abbott, Germany 
Miglyol Caelo, Germany 
Mouse serum Sigma-Aldrich, USA 
Mounting medium with DAPI Vector Laboratories Inc., USA 
Picric acid Sigma-Aldrich, USA 
Picrofuchsin solution Merck Millipore, Germany 
Rabbit serum Sigma-Aldrich, USA 
Resorcin-Fuchsin solution Carl Roth, Germany 
Sirius Red Polysciences, Inc., USA 
Tissue Tek® O.C.T compound Sakura Finetek Europe B.V., 
Netherland 
X-gal Invitrogen, USA 
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3.1.5 Cytokine and Inhibitor 
Table 5: List of cytokines 
Cytokine Manufacturer 
AMD3100 PeproTech, USA 
Recombinant human 
SDF-1α/CXCL12 
PeproTech, USA 
 
3.1.6 Antibodies 
Table 6: List of antibodies 
Antibody 
target 
Specificity Conjugate Application Manufacturer 
Biotin Rat Streptavidin 
APC-Cy7 
FC eBioscience, USA 
Cd115 Monocytes, 
Macrophages 
PE FC eBioscience, USA 
Cd11b Monocytes, 
Neutrophils, 
Macrophages 
FITC FC eBioscience, USA 
Cd31 ECs PE-Cy7 FC Abcam, UK 
Cd31 ECs purified IFS Santa Cruz 
Biotechnology, 
USA 
Cd4 T- helper cells FITC FC eBioscience, USA 
Cd45 Leukocytes APC-Cy7 FC BD Biosciences, 
USA 
Cd8 Memory T-cells PE-Cy7 FC eBioscience, USA 
Cxcr4  purified IFS Abcam, UK 
Cxcr4  FITC FC BD Biosciences, 
USA 
Cxcl12  purified IFS R&D Systems, 
USA 
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Goat IgG Goat IgG Cy3 IFS Jackson 
ImmunoResearch, 
USA 
Gr1 (Ly-6C 
and Ly-6G) 
Neutrophils and 
inflammatory 
monocytes 
APC FC eBioscience,  
USA 
Flk1 
(Cd309) 
ECs, hematopoietic 
cells, HPCs  
APC FC eBioscience, USA 
Ki-67 Proliferating cells purified IFS Dako, Denmark 
Mac2 Monocytes, 
Macrophages 
purified IFS Cedarlane, 
Canada 
Mouse IgG Mouse IgG Cy3 IFS Jackson 
ImmunoResearch, 
USA 
Rat IgG Rat IgG FITC IFS Jackson 
ImmunoResearch, 
USA 
Sma SMCs purified IFS Dako, Denmark 
IFS: Immunofluorescent staining; FC: Flow cytometry 
 
 
3.1.7 Assay Kits 
Table 7: List of assay kits 
Assay Kit Manufacturer 
Cobas enzymatic assay Roche, Germany 
Cxcl12 ELISA kit RayBiotech, USA 
Flt-3 ligand ELISA kit (mouse/rat) R&D System, USA 
Lineage Panel BD Pharmingen, USA 
Sphingosine 1 Phosphate assay kit Lpath, USA 
Vegf ELSA kit (mouse) R&D System, USA 
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3.1.8 Software 
Table 8: List of software 
Software Manufacturer 
Diskus  Hilgers, Germany 
FACSDiva BD Biosciences, USA 
FlowJo Treestar, USA 
GraphPad Prism 5 GraphPad Software, USA 
Image J National Institutes of Health, USA 
 
 
3.1.9 Mice 
The Cxcr4-floxed knock-in mouse model125 and the Bmx-CreERT2 transgenic 
mouse line were provided by Prof. Y. Zou (Columbia University, New York, US) 
and by Prof. R.H. Adams (Cancer Research UK-London Research Institute, 
London, UK), respectively, and were crossed with C57Bl/6 Apoe-/- mice to 
create an atherosclerosis-prone background. The presence of the Cre 
transgene was detected using the primers 5’-AAA TAC CTT CAG TTT 
TCATCT-3’ (Cre-F) and 5’-TTG CGA ACC TCA TCA CTC GTT-3’ (Cre-R). The 
presence of a wild-type or loxP-flanked Cxcr4 allele was detected using the 
primers 5’-CAC TAC GCA TGA CTC GAA ATG-3’ (5X4 FS) and 5’-GTG TGC 
GGT GGT ATC CAG C-3’ (3X4 FS), as previously described125. The inclusion 
of a third primer 5’-GTG CTC CTC GGA ATG AAG AG-3’ allowed to 
discriminate between a wild-type (330 bp), floxed (430 bp) or deleted (200 bp) 
Cxcr4 allele after tamoxifen-induced Cre expression. The Cre-reporter mouse 
line Gt(ROSA)26Sortm1Sor (Jackson Laboratory), expressing a lacZ reporter 
gene that is transcriptionally silenced by an upstream floxed stop sequence, 
was crossed with the Bmx-CreERT2+ mouse line to allow investigation of the 
cellular expression pattern of the Bmx-CreERT2 transgene through analysis of 
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β-galactosidase activity after tamoxifen treatment. 
 
 
3.2 Methods 
3.2.1 Mouse Experiments 
3.2.1.1 Mouse Model and Tamoxifen Treatment 
Five- to 7-week old female Bmx-CreERT2+ Cxcr4-floxed Apoe-/- mice (indicated 
as Cxcr4EC-KOApoe-/-) and littermate Bmx-CreERT2- Cxcr4-floxed Apoe-/- 
controls (indicated as Cxcr4EC-WTApoe-/-) were treated with tamoxifen (1mg/20g 
mouse/day, i.p., tamoxifen dissolved in Miglyol) for 5 consecutive days to 
induce Cre-mediated deletion of the floxed Cxcr4-allele in Bmx+ cells. After a 
recovery period of minimal 3 weeks after the first tamoxifen injection, a first 
blood analysis was performed, later referred to as the “baseline control”. Then, 
the mice were fed a western-type diet containing 21% fat and 0.15% 
cholesterol (Altromin, Germany). After one week of high-fat diet, wire-induced 
injury of the common carotid artery was performed. At the indicated time points 
after injury, the mice were sacrificed and the injured carotid arteries and 
peripheral blood were collected for further investigation. 
The Cre-reporter mouse line Gt(ROSA)26Sortm1Sor (Jackson Laboratory), 
expressing a lacZ reporter gene that is transcriptionally silenced by an 
upstream floxed stop sequence, was crossed with a Bmx-CreERT2+ mouse 
line to allow investigation of the cellular expression pattern of the 
Bmx-CreERT2 transgene through analysis of β-galactosidase activity after 
tamoxifen treatment.  
Animal experiments were reviewed and approved by the local authorities 
in accordance with the German animal protection law. 
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3.2.1.2 Wire-induced Carotid Artery Injury 
Using mechanical denudation of the endothelium, restenosis was simulated in 
mouse common carotid arteries. A wire-induced arterial injury was performed 
after one week of high-fat diet.  
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Figure 7: Anatomy of the mouse carotid artery. A wire-induced arterial injury of the 
left commom carotid artery is performed by wire insertion through the left external 
carotid artery (Figure modified from 
http://0.tqn.com/d/biology/1/0/c/X/aortic_arch.png). 
 
 
The mice were anesthetized with 100 mg/kg Ketamine and 10 mg/kg 
Xylazine i.p. and an endothelial denudation of the left common carotid artery 
(CCA) (Figure 7) was induced by a 0.36 mm guide wire through a transverse 
arteriotomy of the left external carotid artery (Figure 8). After a skin incision at 
the left lateral side of neck, the bifurcation area and the left CCA were 
observed by using a dissecting microscope. Loose ligatures were placed 
around the proximal part of the left CCA, external carotid artery (ECA) and 
internal carotid artery (ICA). After occluding the ECA with a distal ligature, the 
blood flow in the left CCA was temporarily interrupted by tying the ligatures 
around the CCA and ICA. In the ECA, a transverse incision was made between 
the ligature of the CCA and the distal ligature of the ECA by using a fine scissor. 
After 1 cm insertion of a flexible 0.36-mm guide wire into the arterial lumen 
through the incision, endothelial denudation was achieved by a 3-pass rolling 
movement of the guide wire. The ECA ligature proximal of the incision was 
then permanently ligated. The ligatures of the ICA and CCA were removed to 
restore the blood flow and skin incisions were closed with sutures. 
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Figure 8: Scheme of wire-induced left carotid artery injury in mice. An endothelial 
denudation of the left common carotid artery (CCA) was induced by a 0.36 mm guide 
wire, which was inserted through a transverse arteriotomy of the left external carotid 
artery (ECA). (Figure modified from the dissertation of Dr. rer. nat. S. Simsekyilmaz) 
 
 
3.2.1.3 Blood Collection, Sacrifice and Carotid Artery 
Preparation 
Peripheral blood was obtained by puncturing the retro-orbital sinus with 
microhematacrit capillary tubes during short-time isoflurane anaesthesia. 
Peripheral blood analysis was performed at 1 day, 5 days, 10 days and/or 3 
weeks after injury. Differential blood cell counts were determined using a 
Giemsa staining (Animal facility, University Hospital Aachen). 
At the indicated time points after injury, the mice were sacrificed by 
injection of an overdose of 250 mg/kg Ketamine and 25 mg/kg Xylazine. Then 
the mice were perfused in situ with PBS followed by 4% PFA fixation solution. 
The injured carotid arteries were carefully isolated, overnight fixed in 4% PFA 
at 4°C, dehydrated and embedded in paraffin. Within a standardized distance 
(0 to 400 µm) from the bifurcation, serial 4 µm transversal sections from the 
Material and methods 
33 
 
paraffin-embedded carotid arteries were collected on glass microscopy slides 
by cutting with a microtome.  
 
 
3.2.2 Histological Stainings 
3.2.2.1 Deparaffinization and Dehydratation 
For paraffin-embedded sections, deparaffinization is needed before 
histological stainings can be performed. After staining, sections were shortly 
dehydrated, Table 9 and 10 show general steps for deparaffinization and 
dehydratation. 
 
Table 9: Protocol of deparaffinization 
Staining Procedure Time 
Xylol  2 x 15 min 
100% isopropanol 2 x 5 min 
96% isopropanol 5 min 
70% isoprpanol 2 x 5 min 
PBS 5 min 
 
Table 10: Protocol of dehydratation 
Staining Procedure Time 
70% isopropanol dip 
96% isopropanol dip 
100% isopropanol dip 
100% isopropanol dip 
Xylol 5 min 
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3.2.2.2 Elastica van Gieson Staining 
Carotid artery sections (10 sections per mouse, each 40 µm separated) were 
stained using the Elastica-van Gieson (EVG) stain at room temperature (RT) to 
determine neointimal lesion size. Images were recorded with a Leica DM2500 
fluorescence microscope and CCD camera. The area of neointima, which is 
the area between lumen and internal elastic lamina, and the area of media, 
which is the area between internal and external elastic laminae, were 
measured and quantified by planimetry using Diskus Software. Mean values 
were derived from the analysis of 10 sections per mouse for neointimal lesion 
size. 
 
Table 11: Protocol of EVG staining 
Staining Procedure Time 
Xylol  2 x 15 min 
100% isopropanol 2 x 5 min 
96% isopropanol 5 min 
70% isoprpanol 5 min 
Distilled water 5 min 
Resorcin-Fuchsin solution 15 min (60°C) 
Distilled water dip 
80% ethanol dip 
Distilled water ─ 
Weigert’s A + B solution 5 min 
Distilled water dip 
0.5% HCl-alcohol dip 
Distilled water ─ 
Picrofuchsin 3 min 
Distilled water dip 
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70% isopropanol dip 
96% isopropanol dip 
100% isopropanol dip 
Xylol 5 min 
Coverslip with Vitroclud mounting medium  ─ 
 
Results: 
Nuclei and elastic fibers: black-brown 
Collagen fibers: orange-red 
Musculature, cytoplasm and erythrocytes: yellow 
 
 
3.2.2.3 ß-Galactosidase Staining 
ß-Galactosidase activity was determined using a whole mount X-gal 
histochemical staining in which the substrate X-gal produces a blue dye when 
cleaved by ß-galactosidase. Mice were anesthetized with 100 mg/kg Ketamine 
and 10 mg/kg Xylazine i.p., exsanguinated and the vasculature was rinsed in 
vivo with cold PBS containing 2 mM MgCl2. After in situ perfusion with a cold 2% 
PFA solution, carotid arteries were isolated, fixed for 15 min in the same 
fixation solution on ice and washed three times in PBS containing 2 mM MgCl2. 
Then, the carotid arteries were incubated overnight at 37°C in a prewarmed 
ß-gal staining solution, containing 1 mg/ml of the substrate X-gal in an X-gal 
reaction buffer (Table 3). The next day, carotid arteries were rinsed with PBS 
until the washing buffer no longer turned yellow. The stained carotid arteries 
were then embedded in Tissue Tek for 2 hours and cryo-sections were 
prepared. ß-Galactosidase staining was visualized using light microscopy. 
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3.2.2.4 Sirius Red Staining 
Collagen content was determined by Sirius Red staining126. Sirius Red is used 
for detecting all types and species of collagen, such as type I to V collagen127. 
Images were recorded with a Leica DM2500 fluorescence microscope and 
CCD camera. The collagen content was analyzed by Image J software. Mean 
values were derived from 3-5 sections per mouse. 
 
Table 12: Protocol of Sirius Red staining 
Staining Procedure Time 
Xylol  2 x 15 min 
100% isopropanol 2 x 5 min 
96% isopropanol 5 min 
70% isopropanol 5 min 
Flowing water  shortly 
0.1% Sirius Red staining solution 1h 
1% HCl 2 min 
Flowing water shortly 
70% isopropanol dip 
96% isopropanol dip 
100% isopropanol dip 
Xylol 5 min 
Coverslip with Vitroclud mounting medium  ─ 
 
 
Material and methods 
37 
 
3.2.3 Immunohistochemistry and Immunofluorescence 
Staining 
Neointimal macrophages, SMCs and ECs were visualized by 
immunofluorescent staining for Mac2, Sma or Cd31, respectively, followed by 
a FITC- or Cy3-conjugated secondary antibody staining. Endothelial 
expression of Cxcr4 and Cxcl12 was quantified after co-staining for Cd31 and 
Cxcr4 or Cxcl12, respectively. Endothelial proliferation was visualized by 
co-staining for Cd31 and the proliferation marker Ki-67114. Appropriate IgG 
antibodies were used as isotype controls. Nuclei were counterstained with 
4',6-diamidino-2-phenylindol (DAPI). Images were recorded with a Leica 
DM2500 fluorescence microscope and CCD camera. Cellular composition and 
endothelial Cxcr4 and Cxcl12 expression were analyzed using image analysis 
software (Diskus Software, Hilgers) without prior knowledge of the genotype. 
Vessel reendothelialization was calculated as the ratio of the length of luminal 
Cd31+ endothelial immunostaining to the total luminal circumference. Mean 
values were derived from 3-5 sections per mouse for all these analyses. 
 
Table 13: Protocol of immunostaining 
Staining Procedure Time 
Xylol  2 x 15 min 
100% isopropanol 2 x 5 min 
96% isopropanol 5 min 
70% isoprpanol 5 min 
PBS 5 min 
Cooking in citrate buffer 2 x 10 min 
PBS  30 min (cooling) 
Blocking solution 30 min 
Primary antibody Overnight (4°C) 
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PBS 2 x 5 min 
Secondary antibody 1 h 
PBS 2 x 5 min 
Vectashield mounting medium with DAPI ─ 
 
 
3.2.3 Flow Cytometry  
Flow cytometry is a technology for characterizing, sorting and quantifying cells 
using fluorescent dye labeled biomarkers. By screening for differences in cell 
size (forward scatter, FSC) and granularity (side scatter, SSC), different cell 
subsets can be distinguished after passing an argon laser. Furthermore, the 
cells can be characterized, sorted or quantified by their association with 
different fluorescent dyes, which are coupled to antibodies recognizing cell 
type-specific biomarkers. 
For this analysis, whole blood obtained from the retro-orbital plexus of 
mice was EDTA-buffered and subjected to red blood cell lysis (Table 3). After 
extracellular staining with an antibody cocktail against Sca1, Flk1 and Cd31, 
flow cytometry was used to analyze circulating Sca1+Flk1+Cd31+ cells. 
Lin-Sca1+ progenitor cells were determined after staining with an anti-Sca1 
antibody and a Mouse Lineage Panel (Cd3ε, Cd11b, Cd45R, Gr-1, Ter-119, 
Ly-6G, BD Pharmingen). Cxcr4 surface expression was quantified after 
staining with an anti-Cxcr4 antibody. Sca1+Flk1+Cd31+ cells and Lin-Sca1+ 
cells were analyzed after appropriate fluorescence compensation, using 
FACSCanto-II and FACSDiva software. The obtained data were analyzed after 
using gating strategies based on the appropriate FMO (fluorescence minus 
one) controls with the help of the FlowJo analysis program (Treestar). 
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3.2.4 ELISA 
The enzyme-linked immunosorbent assay (ELISA) is a widely-used technique 
to detect and quantify a specific target antigen or protein in fluid such as serum, 
plasma or cell culture supernatants. With a sandwich-based principle (Figure 
9), the proteins of interest are bound between capture antibodies and 
enzyme-linked detection antibodies. After utilizing chromogenic substrates, the 
enzyme generates a detectable signal, and the target protein can be detected 
and measured by a spectrophotometric reader at specific wavelengths. 
In this study, plasma and bone marrow Cxcl12 concentrations were 
determined using a mouse Cxcl12 ELISA kit (RayBiotech). This kit employs a 
96-well plate coated with an antibody specific for mouse Cxcl12. The 
standards and samples were pipetted into the wells and incubate for 2.5 hours 
at RT. After thoroughly washing the wells, a biotinylated anti-mouse Cxcl12 
antibody was added and the plate was incubated for 1 hour at RT with gentle 
shaking. The unbound biotinylated antibody was washed away in a second 
washing step. Horseradish peroxidase (HRP)-conjugated streptavidin was 
pipetted into the wells, following with 45 minutes of incubation time at RT with 
gentle shaking. The wells were again washed and a tetramethylbenzidine 
(TMB) substrate solution was added to the wells and incubated for 30 minutes 
at RT in the dark with gentle shaking. After quenching the reaction by adding 
stop solution to the wells, the color in the wells changed from blue to yellow, 
with the color in proportion to the amount of Cxcl12 bound. The plate was 
immediately read by a plate reader (Infinite M200) and the absorbance 
intensity was measured at a wavelength of 450nm. 
Similarly, the plasma concentrations of Vegf, S1P and Flt-3 ligand were 
determined separately using mouse ELISA kits and measured at demanded 
wavelengths.    
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Figure 9: The sandwich ELISA. A, A plate coated with a capture antibody. B, The 
sample or standard is added and bound to capture antibody. C, An enzyme-linked 
detection antibody is added. D, A chromogenic substrate is applied, resulting in a 
color change and then absorbance can be measured. 
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3.2.5 In vitro Scratch Assay 
The scratch assay is a method used for mimicking the endothelial cell 
response after mouse carotid artery injury and quantifying the speed of wound 
closure, which is influenced both by cell migration and proliferation. Cells are 
grown to confluency and a wound (“scratch”) is introduced by dragging a thin 
pipette tip128. Migration of cells into the wounded area is being analyzed under 
different conditions of cell stimulation. 
Human aortic endothelial cells (HAoECs) were purchased from PromoCell, 
plated on cell culture dishes coated with collagen and cultured in Endothelial 
Cell Growth Medium MV, according to the manufacturer’s recommendations. 
Cells were grown to confluency and were left untreated or were prestimulated 
for 8 hours with CXCL12 (Recombinant human SDF-1α/CXCL12, 100 ng/ml, 
PeproTech), AMD3100 (1 µg/ml, PeproTech) or a combination of both. After 
wound introduction and 20 hours of migration under ongoing stimulation, 
microscopic pictures were taken using phase contrast microscopy. For each 
well, 10 consecutive microscopic pictures were taken at the start and end of 
the migration assay and were overlaid, and the area and number of cells that 
migrated into the wound area was quantified using Diskus software. 
 
 
3.2.6 Quantification of Plasma Lipids  
Plasma cholesterol and triglyceride levels were quantified using enzymatic 
assays (Cobas, Roche) according to the manufacturer’s protocol. The plasma 
and standards were diluted with 0.9% NaCl and after adding a chromogenic 
reagent for 30 minutes at RT, the absorbance in plasma was measured at a 
wavelength of 505 nm by a 96-well plate reader. 
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3.2.7 Statistical Analysis 
Data are represented as means ± SEM and were analyzed using a t-test, 
1-way ANOVA with Newman-Keuls post-test or 2-way ANOVA with Bonferroni 
post-test, as appropriate (GraphPad Prism 5). P<0.05 was considered 
statistically significant. 
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4 Results 
4.1 Analysis of Endothelial Cxcr4 Deletion Using the 
Bmx-CreERT2 Transgene  
To investigate the role of endothelial Cxcr4 in neointimal hyperplasia following 
carotid artery injury, Cxcr4-floxed Apoe-/- mice were crossed with mice expressing 
the tamoxifen-inducible Bmx-CreERT2 transgene. A previous study has reported 
that Bmx is highly expressed in arterial ECs and endocardium, but not in venous 
endothelium129. In tamoxifen-treated Bmx-CreERT2 ROSA reporter mice, 
β-galactosidase activity was detected in the endothelial layer of carotid arteries, 
showing a specific and intense blue staining (Figure 10A), which confirmed that 
the Bmx-CreERT2 transgenic mouse line is suitable to induce a conditional gene 
deficiency in the endothelium of carotid arteries.  
  
 
Figure 10: Efficient deletion of endothelial Cxcr4 in Cxcr4EC-KOApoe-/- mice. A, 
β-Galactosidase activity in the carotid artery from tamoxifen-treated Bmx-CreERT2 ROSA 
reporter mice. Scale bar = 100 µm. B, Quantification of Cxcr4-expressing endothelium in 
carotid arteries from Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice 3 weeks after injury. 
The graph displays the Cxcr4+Cd31+ luminal length as % of the total Cd31+ luminal length. 
Represented are means ± SEM; n=8-13; ***P<0.0001; two-tailed t-test.  
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Cxcr4EC-WTApoe-/-      Cxcr4EC-KOApoe-/- 
 
 
 
 
Figure 11: Representative pictures of endothelial Cxcr4 expression in 
Cxcr4EC-KOApoe-/- mice. Representative images of Cxcr4-expressing endothelium in 
carotid arteries from Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice 3 weeks after injury, 
based on staining of carotid artery sections for Cd31 (red), Cxcr4 (green) and DAPI (blue), 
showing more Cxcr4+ ECs (yellow, indicated with arrows) in Cxcr4EC-WTApoe-/- vs 
Cxcr4EC-KOApoe-/- mice. Scale bars = 100 µm.
Cxcl12/
DAPI 
Cd31/
DAPI 
Cxcl12/
Cd31/ 
DAPI 
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Three weeks after carotid artery injury, endothelial Cxcr4 expression was 
analyzed in carotid artery sections from Cxcr4EC-KOApoe-/- and Cxcr4EC-WTApoe-/- 
mice using double immunofluorescence staining for Cd31 and Cxcr4. Cxcr4 
expression was evident in around 75% of the endothelial layer of 
Cxcr4EC-WTApoe-/- mice, comparing with nearly 25% in Cxcr4EC-KOApoe-/- mice 
(Figure 10 and 11).  
 
 
4.2 Involvement of Endothelial Cxcr4 in Neointimal 
Hyperplasia after Carotid Artery Injury 
To assess the role of endothelial Cxcr4 in neointima formation, a wire-mediated 
vascular injury was induced in the left carotid artery of Cxcr4EC-KOApoe-/- mice and 
Cxcr4EC-WTApoe-/- controls. The mice were fed with a high-cholesterol diet from 
one week before injury. Wire-induced neointimal lesions were quantified three 
weeks and four weeks after injury.  
Three weeks after arterial injury, concentrations of plasma triglycerides and 
cholesterol between both groups did not differ (Figure 12), which means that 
deletion of endothelial Cxcr4 did not influence plasma lipid levels. Also, numbers 
of circulating platelets, leukocytes and leukocyte subsets, including monocytes, 
lymphocytes and neutrophils, were comparable (Figure 13). Furthermore, there 
were no significant changes in the relative frequencies of Gr1low vs Gr1high subsets, 
of B-lymphocytes and of T-cells and its Cd8+ vs Cd4+ subgroups, as quantified by 
flow cytometric analysis (Figure 14). 
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Figure 12: No differences in plasma lipid levels upon endothelial Cxcr4 deficiency. 
Plasma triglyceride and cholesterol concentrations were measured in Cxcr4EC-WTApoe-/- 
and Cxcr4EC-KOApoe-/- mice 3 weeks after carotid artery injury. The graph shows means ± 
SEM; n=8-13. 
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Figure 13: No significant differences in leukocyte and platelet numbers upon 
endothelial Cxcr4 deficiency. Numbers of leukocytes (including monocytes, 
lymphocytes and neutrophils) and platelets were quantified in the peripheral blood of 
Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice at baseline and at different time points after 
injury, as indicated. “Baseline” was measured at least 3 weeks after the first tamoxifen 
injection, but before the start of high-fat diet. The graphs represent means ± SEM; 
n=13-22 (for baseline, 1 day and 3 weeks); n=3-6 (for 5 and 10 days).  
 
 
 
 
Figure 14: No significant differences in leukocyte subset frequencies upon 
endothelial Cxcr4 deficiency. A-D, Analysis of monocytes and Gr1high vs Gr1low 
monocyte subsets (A), T-cells and Cd4+ vs Cd8a+ T-cell subsets (B), B-cells (C) and 
neutrophils (D) by flow cytometry of peripheral blood from Cxcr4EC-WTApoe-/- and 
Cxcr4EC-KOApoe-/- mice at baseline and at different time points after injury, as indicated. 
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“Baseline” was measured at least 3 weeks after the first tamoxifen injection, but before the 
start of high-fat diet. The graphs represent means ± SEM; n=5-13 (for baseline, 1 day and 
3 weeks); n=2-3 (for 10 days). 
 
 
Three weeks after injury, neointimal lesion size of injured carotid arteries 
showed an increased trend in Cxcr4EC-KOApoe-/- mice, without reaching statistical 
significance (Figure 15).  
 
 
 
Figure 15: Endothelial-specific Cxcr4-deficiency showed an increased trend in 
neointima formation 3 weeks after wire-induced carotid artery injury. A, 
Quantification of the neointimal and medial area of carotid arteries 3 weeks after vascular 
injury (n=8-12). Graphs represent means ± SEM; two-tailed t-test. B, Representative 
images of neointimal lesions, positioned ~90µm from the bifurcation. Scale bars = 200 
µm. 
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However, after one additional week, the neointimal lesion size of injured 
carotid arteries was significantly increased in Cxcr4EC-KOApoe-/- mice, whereas the 
medial area, luminal area and the area within the external elastic lamina (aEEL) 
were unaltered, compared with control Cxcr4EC-WTApoe-/- mice (Figure 16A-D). No 
effects of endothelial Cxcr4 deficiency on vessel dimensions were observed in the 
absence of injury (Figure 17). These data indicated that deletion of Cxcr4 on 
arterial ECs enhances neointimal hyperplasia after wire-induced arterial injury. 
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Figure 16: Endothelial-specific Cxcr4-deficiency enhances injury-induced neointima 
formation. A-C, Quantification of the neointimal and neointima-to-media ratio (A), luminal 
area (B), medial area and the area within the external elastic lamina (aEEL) (C)  of 
carotid arteries 4 weeks after vascular injury (n=7-11). Graphs represent means ± SEM; 
*P<0.05; one-tailed t-test. D, Representative images of neointimal lesions, positioned 
~90µm from the bifurcation. Scale bars = 200 µm. 
 
 
 
A 
 
B 
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Figure 17: Endothelial Cxcr4 deficiency does not show significant effects on vessel 
dimensions in the absence of injury. A-B, Quantification of luminal area, medial area 
and the area within the external elastic lamina (aEEL) in carotid artery sections from 
uninjured Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice. Graphs represent means ± SEM; 
n=5-6. 
 
 
 
4.3 Cellular Content of Neointimal Lesions in Response 
to Arterial Injury 
We then analyzed the cellular content in the injured carotid artery sections. To 
determine the response of macrophages and SMCs in the neointima after arterial 
injury, carotid artery sections harvested 3 weeks after injury were labeled with an 
antibody recognizing the macrophage marker Mac2 for macrophage quantification 
and with an antibody directed against the SMC marker Sma for SMC quantification. 
Analysis of percentage and absolute number of macrophages in neointimal 
lesions demonstrated an increase in Cxcr4EC-KOApoe-/- mice compared with 
Cxcr4EC-WTApoe-/- mice (Figure 18).  
Conversely, the SMC content in the neointimal lesions was significantly 
decreased in injured Cxcr4EC-KOApoe-/- mice (Figure 19). This was accompanied 
by a marked reduction in neointimal collagen-rich extracellular matrix content in 
Cxcr4EC-KOApoe-/- mice (Figure 20). Thus, endothelial Cxcr4 deficiency triggered 
enhanced injury-induced neointimal lesion formation with a more unstable or 
inflammatory phenotype. 
 
 
 
 
 
 
Results 
52 
 
 
 
 
 
 
Figure 18: Endothelial-specific Cxcr4-deficiency increases the macrophage content 
of the neointimal lesions. Quantification of neointimal macrophages in carotid artery 
sections from Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice after staining for Mac2 (green) 
and DAPI (blue) 3 weeks after injury (n=8-12). Scale bars = 100 µm. Graphs represent 
means ± SEM; *P<0.05; two-tailed t-test. Representative images are shown. 
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Figure 19: Endothelial-specific Cxcr4-deficiency reduces the smooth muscle cell 
content of the neointimal lesions. Quantification of the neointimal SMC content in 
carotid artery sections from Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice after staining for 
Sma (red) and DAPI (blue) 3 weeks after injury (n=8-12). Scale bars = 100 µm. Graphs 
represent means ± SEM; *P<0.05; two-tailed t-test. Representative images are shown. 
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Cxcr4EC-WTApoe-/-     Cxcr4EC-KOApoe-/- 
  
 
Figure 20: Endothelial-specific Cxcr4-deficiency alters the collagen content of the 
neointimal lesions. Analysis of the neointimal collagen content in carotid artery sections 
from Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice by Sirius Red staining 3 weeks after 
injury (n=8-13). Scale bars = 50 µm. A-C, Graphs represent means ± SEM; ***P<0.0001; 
two-tailed t-test. Representative images are shown. 
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4.4 Importance of Endothelial Cxcr4 for 
Reendothelialization of Denudated Arteries 
As reendothelialization plays an important role in limiting injury-induced 
restenosis15, carotid artery sections of injured carotid arteries were stained for 
Cd31, in order to have a view on the influence of endothelial Cxcr4-deficiency on 
the endothelial recovery process after endothelial injury of carotid arteries. Three 
weeks after injury, reendothelialization in the Cxcr4EC-KOApoe-/- mice reached only 
49%, whereas reendothelialization in the Cxcr4EC-WTApoe-/- control mice was 64% 
(Figure 21).   
 
 
 
Figure 21: Endothelial-specific Cxcr4-deficiency reduces reendothelialization. 
Reendothelialization of the vessel wall, quantified after Cd31 staining (red) of carotid 
artery sections from Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice 3 weeks after injury 
(n=8-12). Nuclei were counterstained with DAPI (blue). Scale bar = 200 µm. Graphs 
represent means ± SEM; **P<0.01 with two-tailed t-test. 
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To clarify the role of Cxcr4 in the wound-healing capacity of ECs, a scratch 
migration assay was performed in vitro. HAoECs were cultured in vitro as 
described. Flow cytometry revealed HAoECs to express CXCR4 and respond to 
the CXCR4 ligand CXCL12 as shown by a decreased CXCR4 surface expression 
in response to CXCL12 stimulation (Figure 22).  
 
 
 
Figure 22: Heterogeneous CXCR4 expression on human aortic endothelial cells. 
HAoECs, untreated or stimulated with 100 ng/ml CXCL12 for 22 h as indicated, were 
analyzed for surface CXCR4 expression using flow cytometry and an appropriate isotype 
control. Different cell populations were identified in the FSC-SSC blot (A), showing 
dissimar levels of CXCR4 expression on their cell surface (B-E). Shown is 1 
representative experiment of 2, with n=2-4. Graph represent means ± SEM. 
Representative histograms are shown. *P<0.05 and **P<0.01; one-way ANOVA with 
Newman-Keuls post-test. 
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HAoECs were stimulated with the CXCR4 inhibitor AMD3100, the CXCR4 
ligand CXCL12 or AMD3100 together with CXCL12, respectively, from 8 hours 
before scratching. Twenty hours after scratching and ongoing stimulation, more 
CXCL12-stimulated HAoECs were migrated into the scratched site in comparison 
with control and AMD3100-stimulated cells. Moreover, AMD3100 could slightly 
block migration of CXCL12-stimulated HAoECs compared with CXCL12 
stimulation alone (Figure 23 and 24). Thus, the scratch migration assay showed 
an increased migratory activity of ECs under activating CXCR4 by its ligand 
CXCL12. However, CXCL12 could not enhance proliferation of HAoECs in vitro 
(Figure 25). 
 
  
 
Figure 23: Analysis of scratch migration assay. CXCL12 increases the wound healing 
capacity of ECs in an in vitro scratch assay. Human aortic ECs, untreated or prestimulated 
for 8 h with CXCL12 or AMD3100 as indicated, were scratched and cell migration into the 
wounded area was quantified 20 h later. Left: Analysis of 8-14 scratches from 5 or 2 (for 
CXCL12 + AMD) independent experiments; Right: Analysis of 5-10 scratches from 3 or 1 
(for CXCL12 + AMD) independent experiments. Graphs represent means ± SEM; *P<0.05, 
**P<0.01 and ***P<0.001 with one-way ANOVA with Newman-Keuls post-test. 
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Figure 24: Representative pictures of a scratch migration assay. Human aortic ECs, 
untreated or prestimulated for 8 h with CXCL12 or AMD3100 as indicated, were scratched 
and cell migration into the wounded area was quantified 20 h later. Quantification of 
migrating cells was accomplished by following with the dash lines. Scale bar = 250 µm.
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Figure 25: CXCL12 does not directly enhance basal proliferation of ECs in vitro. 
Human aortic ECs were left untreated or were stimulated with CXCL12 or AMD3100 for 
the indicated amount of time, after which proliferation was quantified (n=3 independent 
experiments, each performed in duplicate). 
 
 
Nonetheless, 4 days after carotid artery injury, we took the carotid arteries out 
for quantification of neointimal endothelial proliferation. The carotid artery sections 
were stained for Cd31 in combination with the proliferation marker Ki67. The 
number of endothelial proliferating cells, revealed as Ki67+Cd31+ cells, was 
significantly reduced in injured carotid arteries from  Cxcr4EC-KOApoe-/- mice 
compared with Cxcr4EC-WTApoe-/- control mice (Figure 26 and 27). 
Together, these results reveal an important role of the chemokine receptor 
Cxcr4 in the proliferative and migratory response of ECs following vascular 
denudation in vivo. 
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Figure 26: Endothelial-specific Cxcr4-deficiency reduces endothelial proliferation in 
injured carotid arteries. Quantification of Ki67+ ECs in carotid arteries of 
Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice 4 days after injury (n=4 each). Graphs 
represent means ± SEM; **P<0.01 with two-tailed t-test. 
 
 
Figure 27: Representative pictures of endothelial proliferating cell staining. 
Representative images of carotid artery sections co-stained for Cd31 (red), Ki67 (green) 
and DAPI (blue) indicate less proliferating ECs (Ki67+Cd31+, light blue, indicated with 
arrows) in Cxcr4EC-KOApoe-/- vs Cxcr4EC-WTApoe-/- mice. Scale bar = 25 µm.  
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4.5 Influence of Endothelial Cxcr4 Deletion on the 
Mobilization of Sca1+Flk1+Cd31+ Cells after Arterial Injury 
As explained in the introduction, previous studies have demonstrated that EPCs 
contribute to an efficient reendothelialization of denudated vessels 20, 42. Although 
markers of EPCs are not well characterized, the analysis of circulating EPCs in 
mice with flow cytometry is regularly performed using Sca1+Flk1+ expression35, 40, 
41
. Moreover, we checked that mouse Sca1+Flk1+ mononuclear cells were also 
Cd31+ (Figure 28).  Thus, we performed studies to examine the level of 
circulating Sca1+Flk1+Cd31+ cells in our mouse models before and after carotid 
artery injury. At least 3 weeks after the first tamoxifen injection but before the start 
of high-fat diet, 6-8 drops of blood were taken from the mice for analysis, which 
were considered as baseline results. The gating strategy of Sca1+Flk1+Cd31+ cell 
analysis is shown in Figure 27. As presented in Figure 28, no differences in 
circulating Sca1+Flk1+Cd31+ cells were observed between Cxcr4EC-WTApoe-/- and 
Cxcr4EC-KOApoe-/- mice at baseline conditions. 
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Figure 28: Analysis of EPCs. Gating strategy of Sca1+Flk1+Cd31+ cells by flow cytometry, 
including the appropriate FMO controls. Representative dot plots are shown. 
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The level of circulating Sca1+Flk1+Cd31+ cells was increased in 
Cxcr4EC-WTApoe-/- mice 3 weeks after vascular injury (Figure 29). Surprisingly, 
circulating Sca1+Flk1+Cd31+ cells were significantly reduced in injured 
Cxcr4EC-KOApoe-/- mice compared to injured Cxcr4EC-WTApoe-/- controls and did not 
show an increased trend over a three weeks recovery period after vascular injury 
(Figure 29).  
 
 
 
Figure 29: Less circulating Sca1+Flk1+Cd31+ cells in injured mice with an 
endothelial-specific Cxcr4-deficiency. Quantification of Sca1+Flk1+Cd31+ progenitor 
cells in the peripheral blood of Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice before or at 
different time points after carotid artery injury, as indicated. The graph represents means ± 
SEM; n=12-20(for baseline, 1 day, 3 weeks) and n=5-6 (for 5 and 10 days); *P<0.05 and 
***P<0.001; one-way or two-way ANOVA with Bonferroni post-test, as appropriate. 
 
 
Comparably, in Cxcr4EC-KOApoe-/- mice there was a significantly reduced 
mobilization of circulating Lin-Sca1+ progenitor cells after injury, compared with 
Cxcr4EC-WTApoe-/- controls (Figure 30 and 31). 
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Figure 30: Analysis of Lin-Sca1+ progenitor cells. Gating strategy of Lin-Sca1+ 
progenitor cells by flow cytometry, including the appropriate FMO controls. Representative 
dot plots are shown.  
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Figure 31: Less circulating Lin-Sca1+ progenitor cells in injured mice with an 
endothelial-specific Cxcr4-deficiency. Quantification of Lin-Sca1+ cells in the peripheral 
blood of Cxcr4EC-WTApoe-/- vs Cxcr4EC-KOApoe-/- mice before or at different time points after 
carotid artery injury, as indicated. The graph represents means ± SEM; n=11-21 (for 
baseline, 1 and 10 days) or n=5-6 (for 3 weeks); *P<0.05; one-way or two-way ANOVA 
with Bonferroni post-test, as appropriate. 
 
 
As previous studies have shown that Cxcr4 mediates the recruitment of 
progenitor cells to neointimal lesions after carotid artery injury21, 31 and that the 
Cxcl12/Cxcr4 axis plays an important role in progenitor cell mobilization from the 
bone marrow to the periphery130, 131, we questioned whether the reduced 
mobilization of Sca1+Flk1+Cd31+ cells in injured Cxcr4EC-KOApoe-/- mice could be 
related to a potential deletion of Cxcr4 in Sca1+Flk1+Cd31+ cells mediated by the 
Bmx-Cre transgene. Analysis of Cxcr4 expression on the surface of circulating 
Sca1+Flk1+Cd31+ cells, as detected by FACS, showed that Sca1+Flk1+Cd31+ cells 
did not show significant differences in surface Cxcr4 expression between 
Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice (Figure 32), as represented by the 
geometric mean fluorescence intensity (gMFI). Thus, these data indicate that the 
reduced Sca1+Flk1+Cd31+ cell level in injured Cxcr4EC-KOApoe-/- is not caused by a 
Cxcr4 deficiency in the Sca1+Flk1+Cd31+ cells themselves. Comparably, there was 
no statistically significant difference in the Cxcr4 expression level on circulating 
Lin-Sca1+ progenitor cells (Figure 33). 
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Figure 32: Comparable expression of Cxcr4 on circulating Sca1+Flk1+Cd31+ cells 
upon endothelial Cxcr4 deficiency. Cxcr4 expression on the surface of circulating 
Sca1+Flk1+Cd31+ cells was analyzed by flow cytometry in Cxcr4EC-WTApoe-/- and 
Cxcr4EC-KOApoe-/- mice before and at different time points after vascular injury, as 
indicated. Displayed is the geometric MFI (gMFI) of surface Cxcr4 after subtraction of the 
FMO control. The graphs represent means ± SEM; n=4-10. Representative histograms 
are shown. 
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Figure 33: No significant effect on Cxcr4 expression on circulating Lin-Sca1+ 
progenitor cells upon endothelial Cxcr4 deficiency. A-C, Cxcr4 expression on the 
surface of circulating Lin-Sca1+ progenitor cells was analyzed by flow cytometry in 
Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice before and at different time points after 
vascular injury, as indicated. Displayed is the gMFI of surface Cxcr4 after subtraction of 
the FMO control. The graphs represent means ± SEM; n=9-12. Representative 
histograms are shown. 
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As Cxcl12 is an important ligand for Cxcr4 and ECs have been shown to 
produce Cxcl12 through a Cxcl12/Cxcr4 positive feedback loop132, we then 
investigated whether the reduced Sca1+Flk1+Cd31+ cell level could be caused by 
a reduced Cxcl12 expression in the injured Cxcr4EC-KOApoe-/- mice, i.e. we 
investigated the regulation of Cxcl12 expression after endothelial deficiency of 
Cxcr4 in the injured mice. The Cxcl12 level was assessed by ELISA after carotid 
artery injury. No significant differences in the Cxcl12 level in plasma or bone 
marrow was observed in Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice after 
vascular injury (Figure 34A).  
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Figure 34: Plasma levels of different stimuli upon endothelial Cxcr4 deficiency. A, 
Cxcl12 concentration in plasma (left panel) or bone marrow (right panel) before or after 
injury, as indicated; n=5-6 (for bone marrow) or n=8-13 (for plasma). B-E, Plasma 
concentrations of Vegf, Flt3-ligand, S1P and Mif, before or after injury, as indicated. 
Measurements of heparin-plasma are presented in separate graphs (D and E, left panels) 
as EDTA-plasma (all other panels), as heparin- vs EDTA-plasma can differentially affect 
absolute ELISA read-outs. n=2-4 (for Mif baseline and 1 day) or n=5-8 (for all others). 
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To explore other potential mechanism underlying the observed effect on 
mobilization of Sca1+Flk1+Cd31+ progenitor cells, plasma concentrations of 
different stimuli involved in this process were quantified. Plasma concentrations of 
Vegf, Flt3-ligand and S1P, which can all influence progenitor cell mobilization, 
were unaltered at different time points after injury (Figure 34B-D). We then 
investigated Mif, as an alternative ligand of Cxcr4 known to mediate EPCs in vitro 
through Cxcr459. Plasma concentrations of Mif were unaltered until 10 days after 
vascular injury. Surprisingly, at later stage the plasma level of Mif was significantly 
increased in Cxcr4EC-KOApoe-/- mice (Figure 34E), which can thus also not explain 
the decreased mobilization of Sca1+Flk1+Cd31+ progenitors. Finally, we 
investigated GM-CSF as another cytokine involved in progenitor cell mobilization, 
but its plasma level stayed below the detection limit. 
Subsequently, Cxcl12 expression on the endothelial layer of the neointima 
was evaluated 3 weeks after vascular injury in both groups of mice. 
Immunostaining of injured carotid artery sections for Cxcl12 and Cd31 revealed 
that Cxcl12 level in vascular endothelium was lower in Cxcr4EC-KOApoe-/- mice 
compared to Cxcr4EC-WTApoe-/- mice after injury (Figure 35 and 36).  
Together, these results suggest that endothelial deficiency of Cxcr4 in 
Cxcr4EC-KOApoe-/- mice reduces the luminally-exposed Cxcl12 level in injured 
vascular endothelium. This may then contribute to the observed reduction in 
circulating Sca1+Flk1+Cd31+ cells, although the underlying mechanism of declined 
mobilization currently remains unclear. The reduced mobilization of 
Sca1+Flk1+Cd31+ progenitor cells upon endothelial Cxcr4 deficiency may be 
involved in the observed reduction in reendothelialization. 
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Figure 35: Reduced Cxcl12 expression in Cxcr4-deficient endothelium. Quantification 
of endothelial Cxcl12 expression in carotid arteries from Cxcr4EC-WTApoe-/- and 
Cxcr4EC-KOApoe-/- mice 3 weeks after injury. The graph displays the Cxcl12+Cd31+ luminal 
length as % of the total Cd31+ luminal length. Represented are means ± SEM; n=8-13, 
***P<0.0001; two-tailed t-test.  
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Cxcr4EC-WTApoe-/-      Cxcr4EC-KOApoe-/- 
 
 
 
 
 
 
Figure 36: Representative pictures of Cxcl12 expression in endothelium. 
Representative images of endothelial Cxcl12 expression in carotid arteries from 
Cxcr4EC-WTApoe-/- and Cxcr4EC-KOApoe-/- mice 3 weeks after injury, based on staining of 
carotid artery sections for Cd31 (red), Cxcl12 (green) and DAPI (blue). Cxcl12+Cd31+ cells 
(yellow) are indicated with arrows. Scale bars = 50 µm. 
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5 Discussion 
5.1 Endothelial Cxcr4-Deficiency Induced Enhanced 
Neointimal Formation with Neointimal Macrophage 
Accumulation, but with Reduced SMC Content 
Under pathological conditions, the chemokine receptor Cxcr4 and its ligand 
Cxcl12 can mediate bone marrow-derived progenitor cell mobilization to the 
periphery30. This has also been shown in context of vascular injury, in which the 
Cxcl12/Cxcr4 axis is associated with neointimal hyperplasia and mobilization of 
bone marrow-derived SPCs after arterial injury21. Treatment with either Cxcr4 
antagonists or Cxcl12 blocking antibodies reduced the mobilization of SPCs and 
neointima formation after vascular injury21, 123, 124. However, the cell type-specific 
function of Cxcr4 in injury-induced neointima formation still remains unknown. 
Especially, the role of Cxcr4 on vascular ECs in reendothelialization of denudated 
vessels has not been described so far.  
In this study, we demonstrated that deficiency of endothelial Cxcr4 enhanced 
neointimal hyperplasia in Cxcr4EC-KOApoe-/- mice compared to Cxcr4EC-WTApoe-/- 
control mice 4 weeks after carotid artery injury. The increased neointima formation 
in Cxcr4EC-KOApoe-/- mice was associated with a higher neointimal macrophage 
content, a reduced content of neointimal SMCs and a lower neointimal collagen 
content (Figure 18-20). Additionally, these mice showed a higher plasma level of 
Mif 4 weeks after vascular injury but no significant differences in early stage 
(Figure 34E). Previously, expression of Mif could be detected mostly in neointimal 
foam cells 2 weeks after injury119. Furthermore, it has been reported that blocking 
Mif in Ldlr-/- mice revealed a lower neointimal plaque size after experimental 
angioplasty118 and blocking Mif in Apoe-/- mice significantly reduced neointimal 
macrophage content of injury-induced lesions119. Therefore, the higher content of 
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neointimal macrophages in injured Cxcr4EC-KOApoe-/- mice may be at least partly 
mediated by the observed increased plasma level of Mif in these mice at late stage 
after arterial injury, driving an increased size and inflammatory phenotype of the 
neointimal lesions. The mechanisms for enhanced Mif plasma levels in injured 
Cxcr4EC-KOApoe-/- mice remain currently unclear.  
It was previously shown that reduced neointima formation in mice treated with 
the Cxcr4 antagonist AMD3465 was associated with a reduced neointimal SMC 
content and a reduced injury-induced mobilization of Lin-Sca1+ progenitor cells in 
the peripheral blood124. Lin-Sca1+ cells have been reported to be increased shortly 
after injury, and Lin-PDGFRβ+ cells were shown to be able to transdifferentiate in 
SMCs in vitro in response to PDGF-BB. Furthermore, injection of sorted Lin-Sca1+ 
cells from Sm22LacZ mice into injured Apoe-/- mice revealed their incorporation into 
neointimal lesions, and their transdifferentiation into PDGFRβ+ SMCs visualized 
by co-staining for β-galactosidase and PDGFRβ. These results led to the 
conclusion that circulating Lin-Sca1+ cells can be recruited to injured vessel giving 
rise to neointimal SMCs10. Therefore, the reduced neointimal SMC content (Figure 
19) in our injured Cxcr4EC-KOApoe-/- mice could be related to the observed 
decrease in Lin-Sca1+ progenitor cell mobilization into the peripheral blood (Figure 
31). However, surface expression of Cxcr4 on Lin-Sca1+ progenitor cells was not 
decreased in Cxcr4EC-KOApoe-/- mice compared with Cxcr4EC-WTApoe-/- control 
mice (Figure 33), suggesting that other factors are involved in the observed 
reduction in progenitor cell mobilization. As mice treated with a Cxcl12 blocking 
antibody revealed reduced neointima formation after arterial injury associated with 
a decreased mobilization of Lin-Sca1+ progenitor cells in the peripheral blood21, we 
hypothesized that reduced Lin-Sca1+ progenitor cells in Cxcr4EC-KOApoe-/- mice 
may be associated with reduced Cxc12 expression levels. This is being further 
discussed in Chapter 5.3. 
Remarkably, there was only a trend for increased neointima in 
Cxcr4EC-KOApoe-/- mice at 3 weeks after injury, without reaching statistical 
significance (Figure 15). However, after one additional week, neointimal lesion 
Discussion 
75 
 
size was significantly increased with a still incomplete and significantly reduced 
reendothelialization in Cxcr4EC-KOApoe-/- mice (Figure 16). In early stage after 
injury, both the Cxcr4EC-KOApoe-/- mice as controls lack endothelium at the injured 
site, so in both groups, macrophages and SPCs can enter the vessel wall to 
contribute to neointima formation. Furthermore, no significant differences were 
observed in the SPC level in peripheral blood up to 10 days after injury. Thus, a 
comparable neointimal hyperplasia can be expected in the first stages after injury. 
Gradually, reendothelialization starts off, but to a lower extent in Cxcr4EC-KOApoe-/- 
mice compared to controls. However, an enhanced infiltration rate of blood cells 
(macrophages and SPCs, contributing to neointima formation) in the injured 
vessel wall of Cxcr4EC-KOApoe-/- mice is counteracted by a reduced mobilization of 
SPCs at later stage. Whereas the absolute amount of infiltrated macrophages is 
significantly increased in neointimal lesions of injured Cxcr4EC-KOApoe-/- mice 3 
weeks after injury, the absolute amount of SMCs is significantly decreased. As a 
net balance, only a trend for increased neointima formation is observed in 
Cxcr4EC-KOApoe-/- mice compared to controls 3 weeks after injury. However, at 4 
weeks after injury, neointimal lesions were found to be significantly larger in 
Cxcr4EC-KOApoe-/- mice compared to controls. With a significant reduction in 
reendothelialization in these mice at this stage, with control mice reaching 70% of 
reendothelialization compared to 50% in Cxcr4EC-KOApoe-/- mice, these data 
suggest an important role for reduced reendothelialization and enhanced 
macrophage filtration to the observed increase in neointima formation at this stage. 
Although SPCs were significantly reduced in Cxcr4EC-KOApoe-/- mice compared to 
controls 3 weeks after injury, this reduction was not able to counteract the 
increased neointima formation driven by reduced reendothelialization and 
enhanced macrophage infiltration. This suggests that in this stage, the role of 
circulating SPCs in neointimal hyperplasia is reduced in comparison to earlier time 
points. Furthermore, the enhanced MIF plasma levels observed in 
Cxcr4EC-KOApoe-/- mice at this stage may further stimulate enhanced neointima 
formation, as explained above in Chapter 5.1, suggesting that from this stage on, 
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macrophages and SPCs can more readily enter the lesion in Cxcr4EC-KOApoe-/- 
mice. Although these cell types both contribute to enhanced neointima, a reduced 
SPC mobilization in Cxcr4EC-KOApoe-/- mice counteracts this effect. 
Altogether, these results indicate that endothelial Cxcr4 is involved in 
neointimal SMC accumulation, associated with the recruitment of Lin-Sca1+ 
progenitor cells. The reduced SMC content in Cxcr4EC-KOApoe-/- mice was 
associated with a small but significant reduction in collagen content, suggesting a 
lower plaque stability. Furthermore, endothelial Cxcr4 deficiency triggered 
neointimal macrophage accumulation, which could be partially driven by an 
increased Mif level at later stage. 
 
 
5.2 Endothelial Cxcr4 Modulates Reendothelialization by 
EC Proliferation/Migration and Sca1+Flk1+Cd31+ 
Progenitor Cell Recruitment  
EPCs are pivotal in contributing to reendothelialization of denudated vessels20, 21, 
whereas chemokine receptor CXCR4 plays an important role in regulating EPC 
mobilization15, 29. In the current study, we observed that reduced 
reendothelialization after carotid artery injury in Cxcr4EC-KOApoe-/- mice was 
related to a decreased presence of proliferating ECs in the injured vessel (Figure 
26). Moreover, this result was also associated with a lower mobilization of 
circulating Sca1+Flk1+Cd31+ progenitor cells after vascular injury (Figure 29). 
Furthermore, as shown in an in vitro scratch experiment (Figure 23 and 24), a 
lower wound-healing, migratory capacity of HAoECs after blocking CXCR4 with its 
antagonist AMD3100 could also contribute to the defective reendothelialization 
after vascular injury in endothelial Cxcr4-deficient mice. 
Reendothelialization has been investigated in many studies, and has been 
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shown to play a crucial, protective role against neointima formation. Whereas 
increased neointima formation has been correlated with decreased 
reendothelialization after injury17, neointima formation is reduced by an 
accelerated regeneration of the endothelium18. For example, endothelial seeding 
on an injured vessel wall of atherosclerotic rabbits significantly reduced neointimal 
hyperplasia and enhanced endothelial recovery, followed by a reduced 
restenosis15. Also, in a porcine model, implantation of ECs after vascular injury 
revealed a delayed neointima formation16. In summary, these data, together with 
our observation that deletion of endothelial Cxcr4 is associated with defective 
reendothelialization and enhanced neointimal hyperplasia after arterial injury, 
support the notion that endothelial Cxcr4 plays a key role in vascular endothelial 
recovery, named reendothelialization, which is inversely associated with 
neointimal hyperplasia after arterial injury. 
One process contributing to reendothelialization is the proliferation and 
migration of uninjured neighboring ECs to the injured site34. Deficiency of 
endothelial Cxcr4 significantly reduced endothelial proliferation at the injured site 
in vivo, driving a lower reendothelialization level. Furthermore, blocking CXCR4 
with its antagonist resulted in a reduced wound-healing capacity of 
CXCL12-stimulated ECs in an in vitro scratch migration assay. Since CXCL12 
could not directly influence the proliferation of HAoECs in an in vitro proliferation 
assay (Figure 25), absence of endothelial Cxcr4-induced effects on EC 
proliferation in injured vessels of Cxcr4EC-KOApoe-/- mice may be regulated by 
additional factors, which are not present in the in vitro proliferation assay.  
Mif, an alternative ligand of Cxcr4, binds not only Cxcr4, but also Cxcr258. It 
has been reported that Cxcr2 contributes to endothelial recovery triggered by its 
ligand KC/Cxcl1 and blockade of Cxcl1 in vivo reduced reendothelialization and 
increased neointima formation after vascular injury32. Furthermore, Cxcr2 
inhibition reduced improvement of endothelial recovery triggered by EPC injection 
following vascular injury31. Therefore, it is possible that the reduced endothelial 
proliferative effect in vivo upon endothelial Cxcr4 deficiency is influenced by a 
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reduced Mif/Cxcr4 or Mif/Cxcr2 stimulatory effect on ECs. The latter could be 
mediated by a direct interaction between Cxcr4 and Cxcr2, or by an indirect 
interaction by binding a joint interaction partner as e.g. Cd7458. 
  Besides the contribution of migration and proliferation of adjacent ECs to 
reendothelialization of injured endothelium, also bone marrow-derived EPCs play 
a pivotal role in reendothelialization after blood vessel injury19-21. For example, 
studies have shown that reendothelialization was enhanced by transplantation of 
EPCs after prosthetic vascular grafting in human23, 24 and vessel injury of rabbits24. 
Moreover, statin therapy promoted the number of circulating EPCs or the homing 
of EPCs to injured sites in rats, and thereby enhanced reendothelialization22. Also, 
through physical exercise the number of circulating EPCs was increased, leading 
to a significant enhancement of endothelial regeneration with decreased 
neointima formation in mice40, 51. Thus, transplanted or circulating EPCs seem to 
contribute to endothelial recovery and vascular repair and in that way may reduce 
the risk on cardiovascular disease19, 44. Conversely, reduced numbers of 
circulating EPCs were associated with endothelial dysfunction and also higher risk 
on cardiovascular disease43, 44. In conclusion, an increased level of (circulating) 
EPCs has been related to an accelerated reendothelialization after vascular injury. 
Similar results were observed in this study. Although the precise cell surface 
markers for definition of mouse circulating EPCs are not well defined, several 
mouse studies used Sca1+Flk1+ as cell markers in flow cytometric analysis for 
quantifying circulating EPCs40, 41. In our study, we similarly gated Sca1+Flk1+ cells, 
which were found to be also Cd31+, for quantifying mouse circulating EPCs. Our 
results showed that a lower endothelial recovery in Cxcr4EC-KOApoe-/- mice was 
associated with a significantly decreased level of circulating Sca1+Flk1+Cd31+ 
progenitor cells compared with Cxcr4EC-WTApoe-/- control mice after carotid artery 
injury. 
In summary, endothelial Cxcr4 induces reendothelialization by proliferation or 
migration of ECs and mediating the mobilization of circulating Sca1+Flk1+Cd31+ 
progenitor cells, resulting in decreased neointimal hyperplasia. 
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5.3 Endothelial Cxcl12/Cxcr4 Axis Involved in the 
Mobilization of Sca1+Flk1+Cd31+ Progenitor Cells 
The chemokine receptor Cxcr4 plays a key role in mediating the recruitment of 
bone marrow-derived progenitor cells to the injured vascular wall121. In this context, 
blockade of Cxcr4 signaling reduced the recruitment of EPCs to injured arteries31. 
In mice with injured carotid arteries, Cxcr4 gene transfer enhanced 
reendothelialization capacity of EPCs122. Moreover, vascular ischemia and injury 
induced an upregulation of the Cxcr4 ligand Cxcl12, inducing injury-induced 
mobilization and/or recruitment of progenitor cells through the Cxcl12/Cxcr4 
axis21,49.  
Although the level of circulating Sca1+Flk1+Cd31+ progenitor cells was 
significantly decreased after carotid artery injury in Cxcr4EC-KOApoe-/- mice 
compared with Cxcr4EC-WTApoe-/- mice, the level of Cxcr4 surface expression on 
circulating Sca1+Flk1+Cd31+ progenitor cells in both groups of mice did not show a 
significant difference (Figure 32). This result suggested that Bmx was not 
expressed on the mouse progenitor cells, when the mice were treated with 
tamoxifen. It also indicated that the reduced level of circulating Sca1+Flk1+Cd31+ 
progenitor cells in the peripheral blood had to be caused by an alteration in the 
attracting chemokine concentration instead of its chemokine receptor Cxcr4 on the 
progenitors. It has previously been shown Cxcl12 is produced after endothelial 
injury123. In this study, the significantly decreased endothelial Cxcl12 staining at 
the injured site in Cxcr4EC-KOApoe-/- mice compared with controls (Figure 35) may 
contribute to the reduced progenitor cell mobilization in these mice, although the 
concentration of Cxcl12 in plasma and bone marrow was not altered (Figure 34A). 
This may reveal that the expression level of Cxcl12 in the Cxcr4-deficient 
endothelial layer is downregulated, which fits with the previous observation that 
endothelial Cxcl12 production is stimulated through a Cxcl12/Cxcr4 positive 
feedback loop132. On the other hand, the observed reduction in endothelial Cxcl12 
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staining may also merely be a consequence of reduced endothelial Cxcr4 
availability in Cxcr4EC-KOApoe-/- mice, leaving less possibility for Cxcl12 to bind 
endothelial Cxcr4. Since Cxcl12 blocking previously resulted in reduced 
reendothelialization after injury41, our observed reduced endothelial Cxcl12 
staining at the injured site of carotid arteries in Cxcr4EC-KOApoe-/- mice may be 
causally associated with decreased reendothelialization. Furthermore, recent 
findings demonstrate that Cxcl12 is involved in the mobilization of EPCs and their 
recruitment to sites of injury or stress41, 111. Increased plasma level of Cxcl12 after 
arterial injury in Apoe-/- mice was previously shown to be associated with 
enhanced mobilization of circulating Lin-Sca1+ progenitor cells123, and blockade of 
Cxcl12 decreased the number of circulating Sca1+Flk1+ EPCs and 
reendothelialization after carotid artery injury41. Based on all these data, the 
reduced staining for Cxcl12 on endothelium at the injured site in Cxcr4EC-KOApoe-/- 
mice may suggest a contribution of luminal Cxcl12 to reduced reendothelialization 
through reduced recruitment of circulating Sca1+Flk1+Cd31+ progenitor cells to the 
injured carotid artery.  
However, the molecular mechanism of reduced mobilization of 
Sca1+Flk1+Cd31+ progenitor cells from the bone marrow into the peripheral blood 
in injured Cxcr4EC-KOApoe-/- mice still remains unclear, as the Cxcl12 level in 
plasma and bone marrow was found to be unaltered in Cxcr4EC-KOApoe-/- 
compared to control mice. In this study, the Cxcl12 level was quantified using an 
ELISA-based measurement of the Cxcl12-α isoform, whereas the antibody used to 
stain for endothelial Cxcl12 on histological sections was able to recognize not only 
the Cxcl12-α isoform but also the Cxcl12-β isoform. It has been reported that 
infiltration of leukocytes in cerebral ischemic tissue is associated with an 
upregulation of endothelial Cxcl12-β, but not of the Cxcl12-α isoform133. Therefore, 
our observation that no differences could be detected in the Cxcl12-α plasma level 
between Cxcr4EC-KOApoe-/- and Cxcr4EC-WTApoe-/- mice, might indicate that the 
reduced recruitment of circulating Sca1+Flk1+Cd31+ progenitor cells in injured 
Cxcr4EC-KOApoe-/- mice may be induced by a reduced plasma level of the Cxcl12-β 
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instead of the Cxcl12-α isoform. Alternatively, other local mobilizing factors could 
possibly directly or indirectly affect the reduced progenitor cell mobilization upon 
Cxcr4 deficiency. VEGF, which is an angiogenic mediator produced by ECs, can 
regulate mobilization and recruitment of EPCs through its receptor VEGFR255. 
S1P, which is a bioactive lipid also produced in ECs and involved in EC migration 
and proliferation, can also mediate EPC mobilization104. In addition, the 
CXCL12/CXCR4 axis has the ability to mediate the production of VEGF134 and 
S1P104, 135. Therefore, we investigated whether Cxcr4 deficiency was associated 
with reduced systemic levels of these mediators, which may then contribute to 
reduced progenitor cell mobilization in our Cxcr4EC-KOApoe-/- mice. However, the 
plasma levels of Vegf and S1P revealed no differences in both groups of mice after 
carotid artery injury, and the same result was obtained for the plasma 
concentration of Flt3-ligand, which plays a role in mobilization of progenitor cells136 
(Figure 34B-D). Thus, our data indicate that the Cxcl12/Cxcr4 axis did not 
influence Sca1+Flk1+Cd31+ progenitor cell mobilization through altered plasma 
levels of these 3 signaling factors in our Cxcr4EC-KOApoe-/- mice. Surprisingly, the 
alternative ligand of Cxcr4, Mif, which can mediate EPCs in vitro through Cxcr459, 
was not altered in plasma until 10 days after vascular injury but was significantly 
enhanced at later stage in plasma of injured Cxcr4EC-KOApoe-/- mice (Figure 34E). 
That can thus also not explain the decreased mobilization of Sca1+Flk1+Cd31+ 
progenitors, but could contribute to the increased content of neointimal 
macrophages in Cxcr4EC-KOApoe-/- mice, as already mentioned in chapter 4.1. It is 
possible that instead of the investigated signaling molecules, other mediators in 
the plasma, which can also regulate circulating Sca1+Flk1+Cd31+ progenitor cell 
mobilization from bone marrow to peripheral blood after arterial injury, are 
influenced by endothelial Cxcr4 deficiency. One possibility is G-CSF, which can 
induce hematopoietic progenitor cell mobilization56. Also, GM-CSF has the ability 
to modulate the recruitment of circulating EPCs to ischemic hind limb in mice57, 
but the plasma level of GM-CSF remained below the detection limit in our study. 
In conclusion, based on the observed reduction in endothelial Cxcl12 staining, 
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a positive Cxcl12/Cxcr4 interaction may influence the recruitment of circulating 
Sca1+Flk1+Cd31+ progenitors to injured sites after arterial vascular injury. However, 
further studies are required to identify the signaling molecules and underlying 
mechanisms contributing to reduced mobilization of progenitor cells into the 
peripheral blood of injured Cxcr4EC-KOApoe-/- mice. Furthermore, a similar 
restenosis study in mice lacking endothelial Cxcl12 could further clarify the role of 
endothelial Cxcl12 in the mobilization of Sca1+Flk1+Cd31+ progenitors and in their 
recruitment to sites of vascular injury. 
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6 Summary 
Balloon angioplasty or stent implantation is one of the therapeutic strategies for 
treatment of atherosclerosis. However, mechanical denudation of the endothelium 
and the associated formation of a neointimal lesion are major limitations of these 
techniques. Injury-induced neointimal hyperplasia can cause a re-narrowing of a 
dilated artery, called restenosis, and may even be associated with thrombosis in 
case of an unstable neointimal plaque. Reendothelialization plays an important 
role in protecting against injury-induced neointima formation, and chemokines and 
their receptors are also involved. The Cxcl12/Cxcr4 axis has been reported to 
mediate the mobilization of SMC progenitors, driving injury-induced neointimal 
hyperplasia. This study focused on the role of endothelial Cxcr4 in neointima 
formation. The effect of an endothelial-specific Cxcr4 deficiency on neointimal 
hyperplasia following carotid artery injury was investigated using Cxcr4EC-KOApoe-/- 
mice, in which absence of endothelial Cxcr4 could be induced by tamoxifen 
treatment.  
Endothelial Cxcr4 deficiency significantly increased neointima formation after 
wire-induced carotid artery injury in Cxcr4EC-KOApoE-/- mice. A higher content of 
neointimal macrophages was detected in the neointimal lesions, whereas the 
neointimal SMC and collagen content were decreased. This was associated with a 
significant reduction in reendothelialization and EC proliferation in injured 
Cxcr4EC-KOApoE-/- carotid arteries compared to Cxcr4EC-WTApoE-/- controls. 
Moreover, in an in vitro scratch assay, treatment of human ECs with CXCL12 
significantly increased their wound-healing capacity, which could be reversed with 
the CXCR4 antagonist AMD3100. Furthermore, flow cytometric analysis revealed 
a reduced mobilization of circulating Sca1+Flk1+Cd31+ and Lin-Sca1+ progenitors 
after vascular injury in Cxcr4EC-KOApoE-/- mice, although their surface expression of 
Cxcr4 was not changed. No difference could be detected in plasma concentrations 
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of Cxcl12, and also plasma levels of Vegf, S1P or Flt3-ligand, which are able to 
mediate progenitor cell mobilization, were unchanged. However, 
immunofluorescent staining demonstrated a significant reduction of local 
endothelial Cxcl12 in injured carotid arteries from Cxcr4EC-KOApoE-/- mice. 
In summary, Cxcr4 and the Cxcl12/Cxcr4 axis play a protective role in wire 
injury-induced neointima formation by promoting reendothelialization and 
mediating EC migration and proliferation to the site of injury, as well as by 
mediating the mobilization of circulating Sca1+Flk1+Cd31+ progenitor cells (often 
referred to as circulating EPCs) to the periphery. For understanding the role of 
endothelial Cxcl12 in mobilization of circulating Sca1+Flk1+Cd31+ progenitors, a 
similar restenosis study in mice lacking specifically endothelial Cxcl12 is required in 
future. 
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7 Zusammenfassung 
Ballon-Angioplastie oder Stent-Implantation ist eine der therapeutischen 
Strategien zur Behandlung der Atherosklerose. Diese Methoden werden 
allerdings durch die mechanische Denudation und die damit einhergehende 
Enstehung einer neointimalen Läsion eingeschränkt.  Die neointimale Läsion 
kann eine erneute Verengung des Lumens, die sogenannte Restenose,  
induzieren, welche letztlich in einem unstabilen neointimalen Plaque sogar zur 
Thrombose führen kann. In der Neointimalbildung spielt die Reendothelialisierung 
eine wichtige Rolle, wobei auch Chemokine und ihre Rezeptoren involviert sind. 
Von der Cxcl12/Cxcr4 Achse wurde berichtet, dass sie die Mobilisierung der 
glatten Muskelvorläuferzellen vermittelt und dabei die Verletzungs-induzierte 
neointimale Hyperplasie beeinflusst. Der Fokus dieser Studie lag auf der Rolle des 
endothelialen Cxcr4 in der Neointimabildung. Der Effekt der Endothel-spezifischen 
Cxcr4 Deletion auf die neointimale Hyperplasie nach Karotidenschädigung wurde 
in Cxcr4EC-KOApoe-/- und Cxcr4EC-WTApoe-/- Mäusen untersucht. Die Defizienz von 
endothelialem Cxcr4 konnte durch eine Tamoxifenbehandlung induziert werden. 
In Cxcr4EC-KOApoe-/- Mäusen erhöhte der endotheliale Cxcr4-Mangel deutlich 
die Neointimabildung nach von Draht induzierter Verletzung der Halsschlagader. 
Ein höherer Anteil von neointimalen Makrophagen wurde in den neointimalen 
Läsionen beobachtet, während der Anteil von neointimalen glatten Muskelzellen 
und Kollagen verringert wurde. Im Vergleich zu Cxcr4EC-KOApoe-/- Kontrollen 
konnte eine signifikante Reduktion der Reendothelialisierung und 
Endothelzellenproliferation in verletzen Cxcr4EC-KOApoe-/- Halsschlagadern 
beobachtet werden. Die Stimulation von humanen Endothelzellen mit CXCL12 im 
in vitro Scratch Assay erhöhte signifikant ihre wundheilende Kapazität, während 
die mit CXCR4-Antagonist AMD3100 behandelten Endothelzellen einen 
umgekehrten Effekt zeigten. Weiterhin zeigte die Duchflusszytometrieanalyse 
eine reduzierte Mobilisierung von zirkulierenden Sca1+Flk1+Cd31+ und Lin-Sca1+ 
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Vorläuferzellen nach Gefäßverletzung in Cxcr4EC-KOApoe-/- Mäusen, obwohl die 
Oberflächenexpression von Cxcr4 nicht verändert war. Kein Unterschied konnte in 
den Plasmakonzentrationen von Cxcl12, und auch Vegf, S1P oder Flt3-Ligand 
detektiert werden, welche die Mobilisierung der Vorläuferzellen vermitteln können. 
Allerdings konnte per Immunofluorezenzfärbung eine signifikante Reduktion des 
lokalen luminalen endothelialen Cxcl12 in verletzen Halsschlagadern von 
Cxcr4EC-KOApoe-/- Mäusen gezeigt werden. 
Zusammenfassend, spielen Cxcr4 und die Cxcl12/Cxcr4 Achse eine 
schützende Rolle in der Drahtverletzungs-induzierten Neointimabildung durch die 
Beförderung der Reendothelialisierung und der EC-Migration und Proliferation an 
der verletzten Stelle, als auch durch Rekrutierung von zirkulierenden 
Sca1+Flk1+Cd31+ Vorläuferzellen, die oft als zirkulierende EPCs bezeichnet 
werden. Zum Verständnis der Rolle des endothelialen Cxcl12 in der Mobilisierung 
der zirkulierenden Sca1+Flk1+Cd31+ Vorläuferzellen, ist in Zukunft eine ähnliche 
Restenose-Studie mit Mäusen, die eine Endothel-spezifische Deletion von Cxcl12 
haben, nötig. 
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